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Summary
With the complete knowledge about the DNA sequence of human and other model
organisms like yeast, the foundation for a new, technology-driven era of biological
research was laid at the beginning of this millennium. The availability of quantita-
tive DNA and RNA information increased due to improved sequencing technology
based on these reference genomes. This wealth of data has enabled us to ask bio-
logical questions of cause and consequence at nucleotide resolution genome-wide.
In this work I investigated the consequences of DNA variation on RNA expression
using sequencing data in two projects.
The first project distinguishes between controversial mechanisms that confer
robustness to gene expression against regulatory variants. Previous studies sug-
gested widespread buffering of RNA misexpression on protein levels during trans-
lation. We do not find evidence that translational buffering is common. Instead,
we find extensive buffering at the level of RNA expression, exerted through neg-
ative feedback regulation acting in trans, which reduces the effect of regulatory
variants. Our approach is based on a novel experimental design in which allelic
differential expression in a yeast hybrid strain is compared to allelic differential
expression in a pool of its spores. Allelic differential expression in the hybrid is
due to cis-regulatory differences only. Instead, in the pool of spores allelic differ-
ential expression is not only due to cis-regulatory differences but also due to local
trans effects that include negative feedback. We found that buffering through such
local trans regulation is widespread, typically compensating for about 15% of cis-
regulatory effects on individual genes. Negative feedback is stronger not only for
essential genes, indicating its functional relevance, but also for genes with low to
middle levels of expression, for which tight regulation matters most. We suggest
that negative feedback is one mechanism of Waddington’s canalization, facilitat-
ing the accumulation of genetic variants that might give selective advantage in
different environments.
In the second project we develop a bioinformatic pipeline that improves the
diagnosis of Mendelian disorders using RNA sequencing. Mendelian disorders can
be caused by DNA variants in a single gene. However, the causal variants are
hard to identify due to low sample numbers and often complex disease pheno-
types. Accordingly, about 70% of patients with suspected Mendelian disorders
remain undiagnosed after whole exome sequencing. This lack of diagnosis could
be explained by disease-causing variants in non-coding regions. Whole genome
sequencing facilitates the discovery of all genetic variants, but their sizeable num-
ber, coupled with a poor understanding of the non-coding genome, makes their
prioritization challenging. Here, we demonstrate the power of RNA sequencing to
provide a confirmed genetic diagnosis for 10% (5 of 48) of undiagnosed mitochon-
drial disease patients and identify strong candidate genes for patients remaining
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without diagnosis. We found a median of 1 aberrantly expressed gene, 5 aberrant
splicing events, and 6 mono-allelically expressed rare variants in patient-derived
fibroblasts and established disease-causing roles for each kind. Private exons often
arose from sites that are weakly spliced in other individuals, providing an impor-
tant clue for future variant prioritization. One such intronic exon-creating variant
was found in three unrelated families in the complex I assembly factor TIMMDC1,
which we consequently established as a novel disease-associated gene. In conclu-
sion, our study expands the diagnostic tools for detecting non-exonic variants of
Mendelian disorders and provides examples of intronic loss-of-function variants
with pathological relevance.
In summary, both projects not only showed the conceptual benefit of a joint
DNA-RNA analysis, but also provided statistical models and bioinformatic tools
that can be used to drive future studies.
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Chapter 1
Introduction
1.1 Biological background
Life is organized in cells that separate living matter from non-living matter. Cells
store their building plan in a molecule called Deoxyribonucleic acid or short DNA.
In order to reproduce, the mother cell duplicates its DNA and passes it to the
daughter cell. The information encoded in the DNA gets activated via transcrip-
tion of certain regions (genes) into Ribonucleic acids (RNAs), also called gene
expression. These RNAs can perform already many essential functions in a cell,
but most work is done by proteins that are created by translating some of the
RNAs. This cascade of activating DNA information by transcription into RNA
and consequently translation into proteins is called the central dogma of biology
[5, 6].
During the lifetime of an organism spontaneous mutations can occur in the
DNA and change its sequence and thereby its stored information about the cells
building plan. These mutations can be passed to the next generation and can
later be identified as inborn variants to the reference genome of the corresponding
organism. This is common for both uni-cellular organisms like yeast and complex
multi-cellular organisms like humans.
Most inborn variants have no effect on the organism as whole, although they
are present in every cell. This buffering of variant effects is achieved in part by
regulation of the different steps from transcription of genes, translation of RNA
into proteins, and their corresponding degradation. Consequently, variants that
are not too deleterious can accumulate, which might change the regulation of gene
expression at some point enough to form a new species. However, the time scale
for new species to form is within millions of years. To this day, it is not fully
understood which gene regulatory mechanisms buffer the consequences of DNA
variation.
Inborn variants in essential genes can be lethal for the affected organism. Other
inherited variants can lead to severe diseases. These two types of variants are the
most extreme with respect to organismal phenotype and correspondingly rare. So
is the prevalence for a disease that can be caused by these variants. For example
the European Union defines a disease as rare, if it affects less than 1 in 2,000
individuals1 (see also this recent article [7]). More than 8,000 rare diseases are de-
1 Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December
1999 on orphan medicinal products (celex:32000R0141).
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scribed in Orphanet2, an online database with 40 countries contributing. Many of
these rare diseases have genetic origin and are inherited according to Mendel’s laws
– Mendelian diseases. Such rare Mendelian diseases are hard to diagnose and treat,
because there are few individuals with the same disease, their clinical symptoms
are often severe and the treating clinician is by chance seldom an expert for the
corresponding disease. The consequence for patients is often an odyssey of various
clinical tests that try to diagnose the cause. Therefore a genetic approach that
can improve the diagnosis of rare Mendelian diseases would help many clinicians
and patients.
1.1.1 History of early genome sequencing
In 1965 Holley and Sanger together with their colleagues were the first to determine
not only the composition of nucleic acids of a RNA molecule, but also its sequence
[8, 9]. RNA was partially digested by ribonuclease and fractionated across two
dimensions according to its length and base composition. The beginning of nucleic
acid sequencing also started a new research field driven by technological advances.
In contrast to ribonuclease digestion, Wu and colleagues used DNA polymerase to
incorporate radioactive nucleotides, one at a time to determine their sequence at
overhanging 5’ ends in a phage [10, 11]. With these techniques available the first
complete RNA sequence of the coat protein and shortly after the complete RNA
genome of the bacteriophage MS2 was sequenced [12, 13]. The next step forward
came with the separation of nucleic acid fragments via polyacrylamide gels [14, 15],
but the leap towards the sequencing era came with the chain-termination technique
by Sanger [16]. Here, mixing of radiolabelled dideoxynucleotides together with
normal deoxynucleotides for DNA extension produces fragments of all possible
lengths in a single reaction (Fig 1.1). The introduction of dideoxynucleotides
improved not only protocol duration but also complexity to allow sequencing of
more complex organisms. Shortly after, Sanger and colleagues sequenced the first
complete DNA genome of bacteriophage φX174 [17].
The sequencing of the human genome [19, 20] around the millennium was
still based on modifications of the Sanger sequencing technique [16]. Complete
biological understanding of humans was the goal of the sequencing project, i.e.
understanding disease, diversity and aging. Yet, the first findings were almost
disappointing: 30,000 - 40,000 genes, only twice as many as in worm or fly [19].
With these two landmark studies the foundation was laid for the next generation
of sequencing technology. The history of sequencing is also nicely reviewed in [18].
1.1.2 Rapid developments in high throughput sequencing
The completion of the human genome together with model organisms allowed to
develop a new generation of sequencing building upon these reference genomes [21,
22]. The first of the next generation sequencers was developed by 454 Life sciences
corporation and relies on pyro-sequencing in picoliter-sized wells [23]. However,
they were outperformed by Illumina, which is now the most common sequencing
2 Orphanet: an online rare disease and orphan drug data base. ©INSERM 1997. Available
on http://www.orpha.net. Accessed 10 April 2017.
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Figure 1.1: First-generation DNA sequencing technologies. Taken from Ref
[18](Fig 1). Example DNA to be sequenced (a) is illustrated undergoing either
Sanger (b) or Maxam–Gilbert (c) sequencing. (b) Sanger’s ‘chain-termination’
sequencing. Labeled ddNTP nucleotides of a given type are included in DNA
polymerization reactions at low concentrations. Therefore in each of the four
reactions, sequence fragments are generated with 3’ truncations as a ddNTP is
randomly incorporated at a particular instance of that base (underlined 3’ terminal
characters). (c) Maxam and Gilbert’s ‘chemical sequencing’ method. DNA must
first be labeled, typically by inclusion of radioactive P32 in its 5’ phosphate moiety
( P○). Hydrazine removes bases from pyrimidines (cytosine and thymine). Acid
can be used to remove the bases from purines (adenine and guanine). Piperidine
is used to cleave the phophodiester backbone at the abasic site, yielding fragments
of variable length. (d) Fragments can be visualized via electrophoresis on a high-
resolution polyacrylamide gel: sequences are then inferred by reading ‘up’ the
gel, as the shorter DNA fragments migrate faster. In Sanger sequencing (left)
the sequence is inferred by finding the lane in which the band is present for a
given site, as the 3’ terminating labelled ddNTP corresponds to the base at that
position. Maxam–Gilbert sequencing (right) requires a small additional logical
step: Ts and As can be directly inferred from a band in the pyrimidine or purine
lanes respectively, while G and C are indicated by the presence of dual bands.
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Figure 1.2: Outline of Illumina genome analyzer sequencing process.
Taken from Ref [26, Fig 1]. (1) Adaptors are annealed to the ends of sequence
fragments. (2) Fragments bind to primer-loaded flow cell and bridge PCR reac-
tions amplify each bound fragment to produce clusters of fragments. (3) During
each sequencing cycle, one fluorophore attached nucleotide is added to the grow-
ing strands. Laser excites the fluorophores in all the fragments that are being
sequenced and an optic scanner col- lects the signals from each fragment cluster.
Then the sequencing terminator is removed and the next sequencing cycle starts.
platform world-wide [24]. The Illumina protocol is structured in three main steps
(Fig 1.2) [25]:
First, the DNA is denatured and fragmented into smaller pieces. Adapters
are added to allow targeted post processing. In the clustering step, each of these
modified fragments gets amplified on the flow cell. A flow cell is a glass plate with
multiple separated reaction lanes. Each lane has two kinds of oligonucleotides
attached to its surface complementary to the two adapters of the fragment. Con-
sequently, the fragments hybridize via base-pairing and a polymerase synthesizes
the complementary strand to the template fragment. The original template strand
gets washed away and only the surface-attached strands remain.
Second, the newly synthesized strands that are attached to the surface on one
end are now amplified by bridging to the other type of oligonucleotides. Here,
the strand bends and hybridizes to a neighboring oligonucleotide with its free end.
A polymerase synthesizes the complementary strand forming a double stranded
bridge. Denaturation leads to two single strands attached to surface of flow cell.
This bridging process is repeated and parallelized over the flow cell to amplify
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template strands for sequencing.
Third, after amplification, sequencing starts at the primer encoded in the
adapter sequence. All four nucleotides carry a base-specific fluorophore and com-
pete for binding at this step. After incorporation of the correct base the identity of
the bound nucleotide is determined by laser-induced excitation and imaging. The
fluorophore gets removed, leaving the growing strand ready for further elonga-
tion. This process is called sequencing by synthesis through reversible terminator
chemistry.
1.1.3 RNA sequencing
The DNA contains functional elements called genes that are transcribed into
RNAs. These RNAs can take over important enzymatic, regulatory, or messenger
functions, such as those RNAs acting in the ribosome. The ribosome for exam-
ple translates messenger RNAs into proteins. Those RNAs are also called coding,
since they encode proteins. Analogously, there are non-coding RNAs with mostly
regulatory functions, and also RNAs that are named after their function, if any.
The collection of all RNAs in a cell is called the transcriptome.
The quantification standard for the transcriptome shifted from microarrays [27,
28] to RNA sequencing (RNA-seq) driven by the developments in DNA sequencing.
Through reverse transcription of RNA into complementary DNA (cDNA) the same
DNA sequencing technologies can be used to quantify the transcriptome [29]. In
2008 many pilot studies determined the transcriptome of model organisms, e.g.
yeast [30] and human [31]. RNA-seq has the following advantages over microarray
technologies [29]: RNA-seq is not limited to existing reference genomes, has lower
background signal, has a higher dynamic range with no upper limit, and it is
also highly accurate with respect to quantitative polymerase chain reaction and
spike-in RNA controls of known concentration.
One difficulty of RNA-seq is to keep the polarity information of the transcript,
i.e. from which of the two DNA strands it originates. Especially in prokaryotes
and lower eukaryotes the genome is very compact, e.g. for fast replication. Here,
compact means not only most of the DNA is encoding transcripts, but also that
different transcripts overlap on opposite strands. Consequently, preserving the
polarity or strand information of a transcript is crucial to distinguish RNAs. Dur-
ing reverse transcriptase of single stranded RNA into double stranded DNA the
polarity information gets lost. However, there are different strategies to overcome
this drawback [32]. For example Parkhomchuk et al. [33] incorporate deoxyuridine
triphosphate (dUTP) instead of deoxythymidine triphosphate (dTTP) during the
synthesis of the second strand. This allows targeted degradation of the second
strand by Uracil-N-Glycosylase (Fig 1.3).
1.1.4 Modeling RNA sequencing data
The latest sequencing systems are creating a constant flood of DNA and RNA
data, together with the need for sophisticated analysis pipelines. With the recent
Illumina’s NovaSeq sequencing system3 it is (soon) possible to produce 10 billion
reads or 3 terabytes of data per run. For this amount of available data it is crucial
3 https://www.illumina.com/systems/sequencing-platforms/novaseq.html
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Figure 1.3: Strand-specific RNA sequencing. Figure is taken from [33, Fig
1A]. Flowchart of the ssRNA-Seq procedure. RNA is shown in red, DNA in green.
Arrows are in the 5’ to 3’ direction. UNG, Uracil-N-Glycosylase; dNTP, deoxynu-
cleoside triphosphate.
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to model gene expression measured via RNA-seq most stringently to extract a high
signal to noise ratio from the data and not be fooled by spurious events.
To quantify RNA-seq reads for the estimation of gene expression each read is
aligned to its originating genome and assigned to the corresponding target tran-
script. This alignment information can be summarized as read counts per gene
which functions as approximation of the corresponding gene product abundance
in the cell. One of the most basic questions asked for in gene expression analysis
is the difference in transcript abundance between two or more biological condi-
tions, i.e. treated versus untreated with respect to a certain stimulus. To assess
significant differences in read counts for a given gene, an appropriate statistical
test should be applied. In one of the first comparisons between microarray and
RNA-seq expression [31], a Poisson distribution was suggested to model the dis-
tribution of read counts, since read counts represent discrete events of a transcript
being present. Furthermore, Marioni et al. [31] showed the potential to overcome
the limitations of microarray-based expression studies. The Poisson distribution
has a single parameter, its mean, and the other parameters are derived from it,
i.e. the variance is equal to the mean. This variance model was shown to be
too restrictive for RNA-seq read count data, producing too many false positives
(type-I error) [34].
The two software packages edgeR and DESeq were the first to model read count
data via a negative binomial distribution [35, 36] allowing for variance larger than
the mean, i.e. over-dispersion. In DESeq the read count Ki,j for gene i in sample
j (with j ∈ [1,m]) is described with a generalized linear model of the negative
binomial with a logarithmic link function:
Ki,j ∼ NB(mean = µi,j, dispersion = αi) (1.1)
µi,j = sjqi,j (1.2)
log2 qi,j =
∑
r
xj,rβi,r (1.3)
where NB is the negative binomial distribution, αi is a gene-specific dispersion
parameter; r corresponds to the number of conditions that are modeled; x is the
design matrix assigning samples j to conditions r; βs are the coefficients that
represent the effect of a condition r on a specific gene i; sj is the size factor of
sample j. Size factors allow to normalize for sample-specific effects, e.g. amount
of material loaded into the sequencing machine. They are estimated with the
median-of-ratios method:
sj = median
i
Ki,j(∏m
j=1Ki,j
)1/m (1.4)
Throughout this thesis the updated DESeq2 [37] is used to model RNA-seq read
count data. It has the advantage of empirical Bayes based shrinkage for dispersion
and fold change estimation. Gene-wise dispersion is estimated via a maximum
likelihood approach which relies only on the data for each gene separately. A
smooth curve is fitted for expected dispersion by expression strength. The final
dispersion estimates are obtained by shrinking the gene-wise estimates towards
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the predicted values. Fold changes are shrunken towards zero also in an empirical
Bayes based way stronger for low counts, high dispersion, or few degrees of freedom
[37].
Consequently, with this software we are not only able to identify differential ex-
pression from RNA-seq data, but also robustly rank differentially expressed genes
based on their fold changes [37].
1.2 Studying consequences of DNA variation
1.2.1 DNA variation drives evolution through gene expres-
sion changes
DNA can affect the phenotype through changes not only in regions encoding pro-
teins, but also in regions regulating gene expression. Already in 1975, King and
Wilson [38] concluded that the differences in protein sequence and biochemical
properties between humans and chimpanzees are too small to explain their phe-
notypic diversity. The crucial differences do not lie in protein-coding, but rather
in regulatory variations that alter gene expression. One of the first genome-wide
studies investigating intraspecies variation for yeast strains was conducted by Brem
et al. [39]. They used microarrays to measure the expression of more than 6,000
genes in two yeast strains and their haploid segregants and systematically iden-
tified local and distant regulation by linkage. Linkage means that the expression
of a gene is linked to its local or some distant genotype. In a parallel study [40],
expression differences between alleles in mice hybrids were proposed to identify
cis-regulation, since the two alleles in a hybrid are subject to the same trans ef-
fects. Trans effects can be caused by regulatory elements that are not inherited
together with the gene. The approaches of Brem et al. [39] and Cowles et al. [40]
were combined not only to achieve a systematic distinction of positional linkage of
an expression Quantitative Trait Loci (eQTL) into local and distant, but also for
mechanistic classification into cis and trans [41]. Ronald et al. [41] investigated
self-linkage of expression in 112 segregants of two laboratory yeast strains in 5,727
transcripts. Looking more detailed into local regulation they selected 77 genes
with strong self-linkage to be tested for allelic differential expression (ADE) in a
diploid hybrid. Of these, 78% showed ADE besides self-linkage classifying them
as cis-regulated. The remaining self-linkage could be explained by a nearby linked
gene or feedback on the gene itself, as demonstrated for AMN1.
The findings and terms of gene expression regulation are nicely reviewed later
[42–44] (Fig 1.4)4. Briefly, if an eQTL is allele-specific, it is regulated through a cis
mechanism; if an eQTL affects expression of both alleles of a diploid organism it
acts through trans. Moreover, local and distant eQTLs are distinguished by their
genomic position with respect to the gene they influence [43].
4Permissions: “Material may be republished in a thesis / dissertation without obtaining
additional permission from Annual Reviews.”
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Figure 1.4: Molecular mechanisms of local and distant regulatory varia-
tion. Figure taken from [43]. (a) Local regulatory variation acts from a position
near the gene of interest. This type of variation can impact gene expression levels
by affecting (i) the binding of regulatory proteins to regulatory sequences, (ii) nu-
cleosome binding or chromatin remodeling to influence chromatin structure, (iii)
sequences that contribute to transcript-specific decay rates to determine mRNA
stability, (iv) transcript structure as determined by the fidelity of intron splicing,
and (v) regulation of the gene by its own product or the product of a gene down-
stream in the transcriptional regulatory network. (b) Distant regulatory variation
acts from a position far from the gene of interest. This type of variation can impact
gene expression levels by affecting (i) the binding of regulatory proteins to distant
regulatory sequences or (ii and iii) regulation of one or more genes directly or at
some point downstream in the transcriptional regulatory network.
12 CHAPTER 1. INTRODUCTION
1.2.2 Quantification of cis and trans regulation in hybrid
organisms
After these conceptual studies on single genes many genome-wide approaches set
out to quantify the different regulatory mechanisms in different species. Tirosh
et al. [45] conducted the first genome-wide study in a diploid hybrid of two lab-
oratory yeast strains still using microarrays to measure gene expression. They
found that cis-regulation drives interspecies differences, whereas trans-regulation
is condition specific for sensory signals. Cis expression differences were confirmed
to shape adaptive expression divergence between species using a RNA-seq ap-
proach again of two yeast strains and their hybrid [46]. After preliminary work
by Wittkopp et al. [47, 48], McManus et al. [49] conducted the first genome-
wide quantification of cis and trans regulation in Drosophila again with the help
of RNA-seq. Mammals followed two years after with another RNA-seq approach,
here on two laboratory mice strains and their F1 hybrid [50].
The analysis of gene regulation across species highly profited from the fast
progress in sequencing technologies. Their common findings report cis-regulatory
changes to contribute more to interspecies differences and the presence of antag-
onistic cis-trans regulation at various levels across species. Yet, conclusion across
biological kingdoms are hard to draw since the statistical methods evolved together
with the measurement techniques. Summarizing, it is still an open question which
mechanisms buffer cis-regulatory differences, although this buffering is crucial for
further evolution.
1.2.3 Possible buffering mechanisms for the effects of reg-
ulatory variants
The introduction presented in this section is part of the manuscript ”Negative
feedback buffers effect of regulatory variants” from Bader et al. 2015 [1].
In 2014, two studies have assessed the role of translation in buffering variations
in RNA expression [51, 52]. In both studies, ADE was compared to allelic differ-
ential translation efficiency estimated from allele-specific ribosome occupancies in
a cross of the yeast species S. cerevisiae and S. paradoxus. ADE indicates effects
of cis variants, i.e. regulatory variants that act on one but not on both alleles of
a gene [40, 53]. Focusing on genes with both a significant ADE and significant
allele-specific translation efficiency differences, these studies reported an excess of
translation efficiency differences opposing to the allelic differential expression. In
contrast, Muzzey et al. [54] reported a genome-wide trend for reinforcing ADE
during translation in the yeast C.albicans. As these studies used distinct statis-
tical procedures and species, it is hard to compare them and conclude about the
generality of these findings. It is appealing to conceive translation as a check point
to counter allelic expression imbalance (Fig 2.1A). However, a general mechanism
that could sense mRNA allelic imbalance and regulate translation accordingly is
hard to imagine. Instead, the most likely explanation for translational buffering
is the selection for compensatory mutations [51, 52]. Hence, variation in transla-
tion efficiency might contribute to buffering but does not appear as an intrinsic
mechanism that yields robustness against newly arisen regulatory variants.
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Alternatively, Denby et al. [55] have proposed that negative feedback control-
ling the level of RNA expression could be a common mechanism to buffer effects
of regulatory variants (Fig 2.1A). Negative feedback would buffer expression dif-
ferences by exerting a stronger repression on alleles with higher expression levels
and a weaker repression on alleles with lower expression levels. Screening for
auto-regulated transcription factors in yeast, Denby et al. [55] found ROX1 to be
under strong negative feedback. Mutant experiments showed that this negative
feedback confers robustness to the expression of ROX1 in the face of naturally
occurring allelic variants present in a set of divergent yeast strains. This study
demonstrated for a single gene that negative feedback could act as a buffering
mechanism for regulatory variants. However, data about the extent of feedback
mechanisms genome-wide and its importance for buffering regulatory variants is
still lacking.
1.2.4 DNA variation in human disease
One way to study the consequences of DNA variation, is to monitor all or as many
DNA differences as possible and associate them with your trait of interest – also
known as a genome-wide association study (GWAS) [56–58]. In a GWAS approxi-
mately 500,000 to almost three million markers [57, 59] are genotyped to compare
case and control subjects, e.g. people suffering from a likely inherited disease
and healthy people with otherwise matching characteristics like ethnicity, age, and
sex. Sequence and copy-number variations can be identified in this hypothesis-
free approach. The first GWASs investigating human disease found strong risk
loci for age-related macular degradation [60] and Parkinson disease [61]. However,
GWASs also come with major limitations: i) the identified loci are spanning more
than thousand bases, they are not as detailed as individual genes or single nu-
cleotide variants, ii) only common alleles can be detected (minor allele frequency
about 5%), and iii) large sample sizes are required for both identification and repli-
cation [57]. One example of the large sample size requirements is the association
of 18 new loci with body mass index in an analysis of 249,796 individuals [59].
The limitations of GWAS do not allow to explain the missing heritability of
complex traits observed for their associated loci [62]. GWAS studies are blind
towards rare variants that might also contribute to common traits. Furthermore,
rare variants can not only contribute to common traits, but a single variant can
also cause a severe disease (Fig 1.5). Since these diseases can be inherited through
the variants according to Mendel’s laws [63] they are called Mendelian disorders.
Their genetic diagnosis can be achieved, e.g. by targeted sequencing of candidate
genes or molecular assays that can capture the effects of variants [64].
1.2.5 Exome sequencing in genetic diagnosis
Parallel to studies on gene regulation, genetic diagnosis got a boost up through
the new sequencing technologies built upon reference genomes. Especially the field
of Mendelian disorders profited from the development of whole exome sequenc-
ing (WES) [66, 67]. WES is agnostic to the disease, consequently among all the
exonic variants that are routinely detected it is possible to find also new disease-
causing variants in contrast to the pre-defined marker set used for GWAS. In the
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first diagnosis study WES of four patients with the rare dominantly inherited Free-
man–Sheldon syndrome was performed and the previously known causal variants
were recovered [67]. This landmark study paved the way for many success stories
of new disease-causing genes being discovered, e.g. for mitochondrial complex I
deficiency [68], recessive Miller syndrome [69] and dominant Schinzel–Giedion syn-
drome [70]. With the growing number of genetic diagnosis studies the need for
standards arose and was discussed by an expert group in 2012 and later published
[71]. One of their key remarks was the need for global sharing of data to build
a resource that can serve as a reference; for example sequencing data for minor
allele frequencies of variants or variant information together with their evidence
for genetic diagnosis. Both goals were achieved shortly after with a database for
disease-causing variants ClinVar [72, 73] and a catalog of WES data of more than
60,000 human individuals [74, 75].
1.2.6 Diagnosis rate of Mendelian diseases
WES has become a cornerstone for genetic diagnosis. This change in routine is
reflected in the number of Mendelian disease genes discovered by year and tech-
nology (see Fig 1 in [76]). Since 2013 this number grew almost thrice as high for
sequencing based discoveries compared to non-sequencing techniques (see Fig 4
in [77]). When diagnosing patients with a high suspicion of a Mendelian disor-
der, WES achieves an overall diagnosis rate of about 30% [77–79]. Within these
unselected patient cohorts, the highest diagnosis rate of about 47% was achieved
by diseases affecting vision [78, 79]. On complex Mendelian phenotypes such as
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mitochondrial disorders with more than 250 known disease-causing genes, diagno-
sis rates with WES vary [80, 81]. Yet, in a set of 53 patients with biochemical
evidence of respiratory chain defects the diagnosis rate of WES reached 60% [82].
1.2.7 Limitations of genome sequencing
WES has proven very useful in genetic diagnosis, however it is limited by design
to the coding part of the DNA, i.e. regions specified by the exon capture kit.
Mendelian disorders are not exclusively caused by these kind of variants. The
straight forward solution to this limitation is to sequence the whole genome to
get all variants from both coding and non-coding regions. This DNA sequence
information is difficult to interpret without a reference database or additional
molecular measurements that corroborate variant frequency or gene function, cor-
respondingly. A pilot study of the WGS5005 program analyzed 156 independent
cases with a broad range of disorders that were suspected to have a strong genetic
component [83]. Overall, a pathogenic variant could be identified in 21% (33/156
cases), whereas 15% (5/33 variants) of these causal variants would likely be missed
by standard WES.
The WGS500 program leaves open questions on the improvements of whole
genome sequencing over WES. Despite the wealth of genomic variation data,
the interpretation of the non-coding genome is challenging. With many ongoing
sequencing projects like the UK10K project [84], the All of Us project6 (discussed
here [85]), or the goal to sequence 100 million chinese people (discussed here [86])
the distribution of rare variants will be better understood, especially with respect
to different populations. However, functional interpretation of these variants with
purely genetic information remains another challenge.
1.2.8 Personalized transcriptomics
One way to overcome the limitation of identifying only vague loci in GWAS is to
measure both genotype and gene expression. With this additional layer of infor-
mation, it was possible not only to identify which genomic regions differ between
case and controls, but also which genes differ in expression. If the expression
changes were limited to one gene for an associated loci, follow-ups to detect the
variant within the associated loci could be more targeted. Analog to studies in
model organisms (section 1.2.2), eQTL studies in mammals started with microar-
rays to measure the expression for a fraction of transcripts [87, 88] up to almost
transcriptome scale in humans [89]. Emilsson et al. [89] were the first to study ex-
pression association with human disease phenotypes in primary tissues, i.e. blood
and subcutaneous fat.
Again, the advances in sequencing technology brought a better quantification
of transcribed RNA: that is a larger dynamic scale, more and new transcripts
[90, 91]. In both studies RNA-seq was performed on lymphoblastoid cell lines of
already genotyped individuals from the HapMap project [92, 93]. They highlighted
the potential of RNA-seq combined with genetic information to investigate new
regulatory mechanisms and haplotypes together with transcript abundance and
5http://www.well.ox.ac.uk/wgs500
6https://www.nih.gov/research-training/allofus-research-program
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structure. Thus, personalized transcriptomics [94] represents another way around
the limitations of WES and interpretability of whole genome sequencing in genetic
diagnosis. Personalized transcriptomics offers not only a second layer of infor-
mation beyond the DNA but also possible functional consequences of regulatory
variants.
1.2.9 RNA features with diagnostic potential
The introduction presented in this section is part of the manuscript ”Genetic di-
agnosis of Mendelian disorders via RNA sequencing” from Kremer, Bader et al.
2016 [3].
With RNA sequencing (RNA-seq), limitations of the sole genetic information
can be complemented by directly probing variations in RNA abundance and in
RNA sequence, including allele-specific expression and splice isoforms. At least
three extreme situations can be directly interpreted to prioritize candidate disease-
causing genes for a rare disorder. First, the expression level of a gene can lie outside
its physiological range. Genes with expression outside their physical range can be
identified as expression outliers, often using a stringent cutoff on expression vari-
ations, for instance using the Z-score [95] or statistics at the level of whole gene
sets[96, 97]. The genetic causes of such aberrant expression includes rare variants
in the promoter [98] and enhancer but also in coding or intronic regions [95]. Sec-
ond, RNA-seq can reveal extreme cases of allele-specific expression (mono-allelic
expression), whereby one allele is silenced, leaving only the other allele expressed.
When assuming a recessive mode of inheritance, genes with a single heterozygous
rare coding variant identified by WES or WGS analysis are not prioritized. How-
ever, mono-allelic expression of such variants fits the recessive mode of inheritance
assumption. Detection of mono-allelic expression can thus help re-prioritizing het-
erozygous rare variants. Reasons for mono-allelic expression can be genetic. A
pilot study validated compound heterozygous variants within one gene as cause
of TAR syndrome, where one allele is deleted and the other harbors a non-coding
variant that reduces expression [99]. Mono-allelic expression can also have epige-
netic causes such as X-chromosome inactivation or imprinting on autosomal genes,
possibly by random choice [100, 101]. Third, splicing of a gene can be affected.
Aberrant splicing has long been recognized as a major cause of Mendelian disorders
(reviewed in ref. [102–104]). However, the prediction of splicing defects from ge-
netic sequence is difficult because splicing involves a complex set of cis-regulatory
elements that are not yet fully understood. Some of them can be deeply located in
intronic sequences [105] and are thus not covered by WES. Hence, direct probing
of splice isoforms by RNA-seq is important, and has led to the discovery of multi-
ple splicing defects based on single gene studies: skipping of multiple exons (exon
45-55) [106] and creation of a new exon by a deep intronic variant in DMD [107],
intron retention in LMNA caused by a 5’ splice site variant [108], and skipping of
exon 7 in SMN1 caused by a variant in a splicing factor binding site [109]. Al-
together, RNA-seq promises to be an important complementary tool to facilitate
molecular diagnosis of rare genetic disorders. However, no systematic study to
date has been conducted to assess its power.
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1.3 Aims and scope of this thesis
In my PhD thesis I studied the consequences of DNA variation by the means of
RNA sequencing data in two ways.
First, I investigate gene expression in two closely related yeast lab strains to
detect and quantify regulatory mechanisms that buffer the consequences of DNA
variation. I will build upon the success in quantifying local and distant as well
as cis and trans regulation. Notably, local trans regulation was never measured
genome-wide. This thesis will fill the gap on gene expression regulation and answer
the following questions:
• What is the amount and direction of local trans regulation?
• How can cis regulatory differences be buffered in general?
• What are the mechanisms of this buffering?
In the second part of this thesis I will combine DNA variation quantified by
WES with RNA-seq data to set new standards for genetic diagnosis of Mendelian
disorders. The following questions will be answered:
• Which RNA features can be used for genetic diagnosis in addition to exome
variants?
• Can RNA features prioritize genes missed by WES analysis?
• Can we build a general pipeline to use RNA-seq for genetic diagnosis?
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Chapter 2
Negative feedback buffers effect
of regulatory variants
The results presented in this section are part of the manuscript ”Negative feedback
buffers effect of regulatory variants” from Bader et al. 2015 [1].
Here, we sought to quantify the extent of buffering by feedback against natu-
rally occurring regulatory variants genome-wide. To this end, we devised a novel
experimental design in which ADE in a hybrid of two yeast strains is compared
against ADE in a pool of spores of the same cross (Fig 2.1B). We distinguish three
types of regulatory variants [42]. First, cis-regulatory variants affect by definition
only the allele of the same chromosome and induce ADE in both the hybrid and
the pool of spores (Fig 2.1C, left column). Instances of cis regulatory elements
include transcription factor binding sites and regulatory elements in the UTR.
Second, local trans mechanisms, which act in trans and are inherited together
with the gene they affect, induce ADE in the pool of spores. However, as any
trans effect [40, 53], local trans mechanisms act in the hybrid unspecifically on
both alleles and thus do not induce ADE in the hybrid (Fig 2.1C, middle column).
Local trans regulation can be due to the product of the gene itself (feedback) or
to another gene in linkage disequilibrium such as a nearby encoded transcription
factor [41]. Local trans regulation can reduce the ADE in the spores compared
to the hybrid, if it counteracts the cis regulation (Fig 2.1B). Third, distant trans
mechanisms, which are encoded on another chromosome or at a distant, unlinked
locus of the same chromosome, are inherited independently of their target genes
in the spores. Hence, effects of distant trans mechanisms are averaged out across
the population of spores and thus do not contribute to ADE (Fig 2.1C, right col-
umn). Altogether, comparison of ADE in the hybrid against the pool of spores
thus enables the dissection of local regulation into cis and local trans (including
feedback) effects.
We find that buffering through local trans regulation is widespread, typically
compensating for 15% of cis-regulatory effects on individual genes. It is stronger
for genes with essential function and with low to middle level of expression. In
contrast, re-analysis of published ribosome profiling data [51] did not support
buffering at the translational level. Altogether, our results indicate that negative
feedback plays an important role in buffering regulatory consequences of genetic
variants.
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Figure 2.1: Tested hypothesis and experimental design (A) Effects of RNA
misexpression due to cis-acting regulatory variants (orange triangle) could be
buffered through (1) negative feedback of a gene product onto its RNA expres-
sion level as investigated here or (2) through compensatory translation efficiency
effects as recently proposed [51, 52]. (B) Allelic differential expression (ADE) was
estimated from allele-specific read counts in RNA-sequencing (right column) from
a cross (F1 generation, top row) of the yeast strains SK1 (red) and S96 (blue) and
compared against ADE from its pool of spores (F2 generation, bottom row). (C)
Cis effects yield to ADE in both the hybrid and the pool of spores (left column).
In contrast, local trans effects including feedback only yield to ADE in the pool of
spores (center column). Distant trans effects do not yield to ADE neither in the
hybrid nor in the pool of spores (being averaged out).
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2.1 Dissecting cis and local trans regulatory ef-
fects
The reference lab strain S96 [110, 111] was crossed with the wild isolate SK1
[112, 113]. Sporulation, germination, and overnight growth of the pool of spores
led to enrichment of alleles due to natural selection as well technical selection for
a single mating type [114–116]. To control for this bias, allele frequencies were
robustly estimated from DNA sequence data of the pools (Methods). S96 and
SK1 are genetically distant strains (0.7% divergence, [113]), allowing investigation
of a large set of regulatory polymorphisms and alleles. We identified 7,231 genes
of a comprehensive S96 transcriptome annotation [117] that are common to both
backgrounds by reciprocal best alignments with at least an identity of 95% (Meth-
ods). Out of these, the 6,934 (96%) genes that showed expression for both alleles
and carried at least one polymorphism were amenable to allele-specific expression
profiling by RNA-sequencing (Fig 2.1B, Methods).
RNA-sequencing showed high reproducibility between biological replicates, though
higher between hybrids than between pools of spores (Supplementary Fig 2.2,
Spearman correlation 0.98 and median coefficient of variation of expression level
of 14% in hybrids versus 0.96 and 24% in spores, respectively). Deep sequenc-
ing led to 6,691 genes (93%, 5,078 coding and 1,613 non-coding) with more than
10 allele-specific reads on average per sample (median 1,044), for which we con-
sidered to have enough data to investigate their allele-specific regulation quan-
titatively. Cis and local trans effects were estimated using a generalized linear
model of allele-specific RNA-sequencing read counts (using the software DESeq2
by [36], Methods). In contrast to standard methods that estimate allelic differen-
tial expression from RNA-sequencing data [46, 49, 118], our approach (i) jointly
modelled all replicates, avoiding summarizations of per-replicate results that do
not take between-replicate variance into account, (ii) modelled over-dispersion of
RNA-sequencing read counts, limiting false positive results in comparison to Pois-
son or binomial models [36], and (iii) flexibly allowed controlling for covariates
with known (genomic allele frequency) or with unknown (replicate, ploidy) effects.
Lack of correlation of cis effect estimates with genomic allele frequency (Supple-
mentary Fig 2.3) and L-shaped distribution of P -values (Supplementary Fig 2.4
center) indicated the validity of the method.
Overall, 984 (15%) genes showed strong and significant cis effects (cis genes,
effect > 1.5-fold and FDR < 0.2, Benjamini-Hochberg correction here and in the
following) and 54 (1%) genes showed strong and significant local trans effects (ef-
fect > 1.5-fold and FDR < 0.2, Supplementary Fig 2.4, Methods). When not
filtering by effect size, the prevalence of cis effects in this cross (23%, 1,552) was
in line with former reports in yeast (∼33%, 1400 of 4140 genes in [45]; 19% cis,
830 of 4282 genes in [46]), fly (18% cis, 1,359 of 7,631 in [119]), and mice (31%
cis, 3149 of 10,090 genes in [50]). Local trans genes were enriched for genes encod-
ing proteins that localize in the extracellular region (Gene Ontology enrichment
[120], Fisher test, FDR= 0.02), in agreement with trans effects acting often due to
variations in sensory processes [45]. Most of the local trans genes do not encode
transcription factors (Methods) in line with the lack of enrichment of transcrip-
tion factors among trans-acting regulatory loci [121] and thus were missed in the
previous transcription factor screen [55]. On the other hand, ROX1 showed no
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Figure 2.2: Biological replicate variation. (A-B) Scatter plot of gene-level
allelic read counts corrected for sequencing depth and genomic allele frequency
(Methods) for hybrids (A) and pools of spores (B). (C-D) Distribution of the
gene-level fold change between the biological replicates for hybrids (C) and pools
of spores (D).
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Figure 2.3: Correction for genomic allele frequency. For the spore pool A
(top) and for the spore pool B (bottom): RNA count ratios (y-axis, top row)
and RNA count ratios corrected for genomic allele frequency (y-axis, bottom row,
Methods) versus genomic allele frequency (x-axis) and respective Spearman cor-
relation (lower right corner). Artificial selection (MAT Locus on chromosome III)
and natural selection (presumably for HAP1 on chromosome XII) leading to ge-
nomic allele frequency imbalance in the pool of spores.
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versus mean sample count (x-axis). Genes with an FDR < 0.2 are highlighted
(red to yellow). Highlighted genes with a fold change greater than 1.5 (solid light
blue line) were considered significant for the corresponding effect (Methods).
evidence for local trans regulation in our study, most likely because its feedback
works under hypoxic conditions [55]. The much smaller amount of genes with
significant local trans effects in comparison to the amount of genes with signifi-
cant cis effects does not prove that local trans effects are less prevalent. Instead,
this difference is likely a consequence of the limited statistical power for calling
local trans effects, which relies on determining a difference between spore ADE
and hybrid ADE. In comparison, there is much higher power to detect cis ef-
fects which mainly relies on determining hybrid ADE. Nonetheless, genes under
documented feedback regulation including PHO84 [122] and AMN1 [41, 121, 123]
were identified (Supplementary Fig 2.5 top). This shows that genuine strong local
trans effects could be detected. Moreover, 14 out of the 54 genes showed complete
buffering of cis effects through local trans regulation, i.e. they exhibited a strong
ADE in the hybrid and essentially equal allelic expression in the pool of spores
(hybrid count ratios larger than 1.5 and spore count ratios smaller than 1.5, ex-
amples in Supplementary Fig 2.5 bottom). Together, these findings indicate that
buffering through local trans regulation might be frequent.
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Figure 2.5: Read counts corrected for sequencing depth and genomic
allele frequency for six local trans genes. Top row shows three genes with at
least 1.5 fold difference between the count ratio (SK1/S96) of the spores, but not
for the hybrid. PHO84 is a reported case of positive feedback [122, 124], which
leads to ADE in the pool of spores but not in the hybrid. AMN1 is known to
regulate itself through a negative feedback loop and to carry a coding mutation in
the reference lab strain that impairs this feedback [41]. In the case of a mutation
affecting the negative feedback loop itself, negative feedback is exerted only in the
half of the spore population that inherited the functional feedback. Thus allelic
differential expression is specific or at least stronger in the pool of spores than in
the hybrid. Consistently, AMN1 showed only allelic differential expression in the
spores. Bottom row shows three genes with at least 1.5 fold difference between
the count ratio of the hybrid strains, but not for the spores. Individual replicate
measures are indicated by black dots.
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2.2 Local trans effects buffer cis effects genome-
wide
As statistical power on individual genes is limited, we also analyzed local trans
regulation genome-wide. In this experimental setup, buffering can only be assessed
for genes showing a cis effect in the first place. For the 984 cis genes, allelic ex-
pression imbalances typically agreed in direction, but were weaker for the pool of
spores compared to the hybrid (Fig 2.6A, mass of the data subdiagonal). To quan-
tify the amount of buffering of cis effects, we defined the buffering coefficient C as
one minus the log-ratio of allele-specific expression in the spores versus the hybrid
(See Methods for definition and unbiased estimation). The buffering coefficient
has a value of 0 in the absence of buffering (equal ADE in the pool of spore and
hybrid), 1 for complete compensation (ADE in the hybrid but no ADE in the pool
of spores). The buffering coefficient is greater than 1 in case of over-compensation
and is negative if local trans effects enhance cis effects. More than half of the genes
with cis effects showed at least partial buffering (60% with C above 0). Local trans
buffering appeared to affect all classes of genes, since no gene ontology category
was significantly enriched (Fisher test, FDR < 0.1). Moreover, no significant asso-
ciation was found between buffering coefficient and gene features that have been
associated with gene expression variability (TATA box) or dosage compensation in
fly (gene length) (Supplementary Fig 2.7). The trend for buffering was robust to
the definition of cis genes as it was still detectable across all genes (Supplementary
Fig 2.8A). Hence, genome-wide cis effects tend to be partially buffered by local
trans-regulatory mechanisms. These local trans mechanisms buffer typically 15%
(Fig 2.6C, median C = 0.148; P = 6.5× 10−15, one-sided Wilcoxon test) of allelic
expression log-ratios caused by cis-regulatory variants (Fig 2.1A).
To compare the amount of buffering by local trans mechanisms against buffer-
ing by translation efficiency, we re-analyzed one ribosome-profiling dataset [51]
following the same statistical procedure as above. Here, the ribosome profiles of
the hybrid substitute for the transcription profiles in the pool of spores (Methods).
A total of 592 genes were identified as having cis differences on RNA expression
(effect > 1.5-fold and FDR < 0.2). For these genes, allelic differential levels of
ribosome-bound RNAs had typically the same extent as allelic differential levels
of expression of the RNAs in the hybrid (Fig 2.6B, mass of the data along the
diagonal; Fig 2.6C, median buffering coefficient -0.058, 54% with C < 0). This
observation was robust with respect to the definition of cis genes, since no support
for translation efficiency buffering was detectable across all genes, too (Supplemen-
tary Fig 2.8B). We did not find an enrichment for translation efficiency opposite
to ADE either when we focused on genes with both a significant ADE and sig-
nificant allele-specific translation efficiency differences as the original study did
(164, 54%, genes out of 303 genes with FDR < 0.2 for both effects had opposing
ADE and translation efficiency, P = 0.17 two-sided Binomial test). Both previous
publications [51, 52] could have been misled by the fact that translation efficiency
estimates were technically anti-correlated with RNA levels estimates [126] and by
the fact that the measurement variance was larger than assumed (Supplementary
information).
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Figure 2.6: Local trans effects, but not translation, buffer ADE (A) Scatter
plot of allele-specific expression ratios in the pool of spores (y-axis) against hybrid
(x-axis) for the genes with cis effect (984 cis genes). For both axes and on a gene
basis, the allele with the lower expression level in the hybrid is taken as reference
(denominator). ADE in the hybrid measures cis-regulatory effects (x-axis). Three
categories of genes are distinguished depending on the resulting ADE in the pool
of spores (y-axis, due to cis and local trans regulation): compensated (dark green
background) with canceled or opposite ADE (over compensation), buffered (light
green) with reduced ADE, and enhanced ADE (purple). Most of the genes are
buffered. (B) Analogous to (A) but for the 592 RNA cis genes of the Artieri et
al. [51] dataset. Ribosomal profiling ratios (y-axis) of a cross between S. cerevisiae
and S. paradoxus are compared against RNA ratios (x-axis) of the same hybrid.
The mass of the data lies at the diagonal indicating that RNA cis effects in the
hybrid are not buffered translationally. (C) Quartiles (boxes) and 1.5 times the
interquartile range (whiskers) of the buffering coefficient for the gene sets from
(A), left and (B), right. The buffering coefficients at RNA level are significantly
greater than zero (left, median = 0.147, P < 6.5×10−15, one-sided Wilcoxon test),
whereas they are not at translational level (right).
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Figure 2.7: Buffering compared to gene features. No correlation between
buffering coefficient and TATA box presence as well as gene length [125] defined
as mean of SK1 and S96 length among cis genes. P -values were computed using a
two-sided Wilcoxon test.
2.3 Local trans buffering is stronger for essential
genes
If local trans regulation confers robustness against regulatory variants, then one
would expect it to be stronger at genes important for fitness. We tested this
hypothesis by classifying genes into three categories with increasing fitness rele-
vance: 1,613 non-coding genes (24%, ncRNA), 4,004 non-essential protein-coding
genes (60%, non-essential), and 1,074 essential protein-coding genes (16%, essen-
tial). The proportion of cis genes in each category was inversely related to fit-
ness relevance (Fig 2.9A), whereby ncRNAs were enriched for cis genes (20%,
P = 1.6 × 10−10, Fisher test) and essential genes were depleted for cis genes
(11%, P = 9.2 × 10−5, Fisher test). This result also held when controlling for
expression level and considering the combination of two FDR thresholds (0.1 and
0.2), with and without fold change cutoff (Supplementary Fig 6.1). The asso-
ciation of cis effects with gene categories is in line with former reports limited
to protein-coding genes [45, 46] and consistent with the idea that selection on
regulatory elements is more important for coding than non-coding genes and for
essential than non-essential genes. Surprisingly, the buffering coefficient and fit-
ness relevance did not correlate (Fig 2.9B). However, stratifying genes into three
equally large groups with low, middle and high average expression levels revealed
that highly expressed genes showed lower buffering coefficients compared to the
two other groups (Fig 2.9C, median buffering coefficient= -0.036 versus 0.284 and
0.202 with P = 3.6 × 10−7 and P = 6.0 × 10−7 for low and middle levels, re-
spectively. Wilcoxon test, Methods, Supplementary Fig 6.2 top). This result held
when considering combinations of FDR and fold change cutoffs as above (Supple-
mentary Fig 6.3). A plausible explanation for this observation is that buffering is
less needed for highly expressed genes because RNAs are produced in excess and
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Figure 2.8: Analysis of buffering trend across all genes (A) Scatterplot of
allelic ratio corrected for sequencing depth and genomic allele frequency in pool
of spores (y-axis) against the hybrid (x-axis) for all genes. We used principal
component analysis to estimate buffering across all genes because the buffering
coefficient is ill-defined for non-cis genes (Methods). The trendline (green) is the
direction of the first principal component. Its slope (0.75) is lower than 1 indicating
genome-wide trend for buffering of cis effects by local trans effects. Note that
this analysis is conservative since larger replicate variance for the pool of spores
(y-axis) than for the hybrid (x-axis) leads to overestimation of the first pincipal
component slope. (B) Scatterplot of allelic ratio in ribosome profiling data (y-
axis) against allelic ratio in ribosome profiling data (x-axis) in the S. cerevisiae x
S. paradoxus hybrid for all genes (data from [51]). The first principal component
is above diagonal (slope=1.90, green line), thus does not provide evidence for
buffering genome-wide at the translational level. Here, the slope overestimation of
the principal component analysis might confound this result. Moreover, because
variance between biological replicates is larger across RNAseq for pools of spores
than for ribosomal profiling across hybrids, a buffering effect as large as the one
seen in the spores would have been detected, if it were present at the translational
level.
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thus variation in their expression level has less phenotypic impact. Consistent with
this hypothesis, the buffering coefficient was found to be positively associated with
fitness relevance when restricted to genes with low and middle levels of expression
(Fig 2.9D, Supplementary Fig 6.2 bottom). These results provide clear evidence
for two regulatory strategies conferring robustness against regulatory variants: Ex-
cess amount of RNA on the one hand, and buffering through local trans regulation
for low to middle levels of expression on the other hand.
2.4 Local trans buffering is primarily due to neg-
ative feedback
Buffering by local trans regulation can be caused by the gene itself (negative feed-
back) or by any other gene in linkage disequilibrium with it. Although negative
feedback provides a simpler explanation for our data since the buffering is accom-
plished without the need for compensatory mutations, both mechanisms could be
at play. To understand which of these two mechanisms is the major contributor
to buffering, we revisited data of a previous study in which protein levels of 730
genes in diploid strains with one gene copy deleted were compared to wildtype
levels [127]. In this experiment, compensatory mutations had no time to occur
since the deletion was introduced artificially. Consequently, only the effect of feed-
back was measured. Springer and colleagues’ screen was technically limited to
non-essential genes and to genes with high levels of expression (63% in the highly
expressed tercile, Fig 2.10A), i.e. for two gene categories for which we detected
lower amounts of buffering than genome-wide. Nonetheless, we found evidence for
buffering in this dataset (Fig 2.10B; median C = 0.055, P = 2.1× 10−15 for [127],
one-sided Wilcoxon-test). Moreover, buffering in these data was comparable to
the amount of local trans buffering we observed for genes with matched properties
(Fig 2.10B, median C = 0.058, Methods and Supplementary information). Hence,
these deletion experiments indicate that negative feedback is the primary mecha-
nism for local trans buffering. A further feature distinguishing negative feedback
from compensatory mutation is that negative feedback also confers robustness to
environmental variations. Consistently, the buffering coefficient of the cis genes
negatively associated with expression response to more than 1,500 environmental
perturbations [45] (median buffering coefficient=0.22 for the low versus 0.07 for
the high tercile of environmental response, P -value = 0.031, one-sided Wilcoxon
test, Fig 2.10C, Supplementary Fig 6.4). Altogether, these results indicate that
local trans buffering is primarily due to negative feedback rather than due to com-
pensatory mutations.
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Figure 2.9: Local trans buffering is stronger for genes important for fit-
ness and with low to middle levels of expression. (A) Proportion of cis
genes by gene category. Essential genes show a lower cis gene proportion than
genome-wide (horizontal line), whereas non-coding RNAs are enriched for cis genes
(P -value from two-sided Fisher test, Error bars indicate 95% confidence intervals
for binomial proportions). (B) Distribution of buffering coefficient for cis genes
grouped by gene category. No significant differences detectable. P -value s are
computed with an one-sided Wilcoxon test with the alternative hypothesis that
essential genes are more buffered than ncRNA, analogously for non-essential. (C)
Distribution of buffering coefficient for cis genes grouped by expression level ter-
cile. Highly expressed genes are less buffered than genes with low and middle
expression levels. P -value s are computed with a two-sided Wilcoxon test. (D)
Same as (B) but for cis genes only at low and middle expression levels. At these
levels of expression, buffering positively associates with fitness relevance category.
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Figure 2.10: Local trans buffering is primarily due to negative feedback.
(A) Proportion of expression levels in [127] dataset (gray) and from cis genes in
this study (blue). Due to technical limitations, Springer and colleagues’ dataset is
enriched for genes with high levels of expression. Error bars indicate 95% confi-
dence intervals for binomial proportions. (B) Quartiles (boxes) and 1.5 times the
interquartile range (whiskers) of Springer and colleagues’ C coefficient (left), of
the buffering coefficient estimated in this study for cis genes with expression level
distribution and gene category matching Springer and colleagues dataset (Meth-
ods, center), and of the buffering coefficient estimated in this study for all cis genes
(right). Springer and colleagues’ C mathematically corresponds to the here defined
buffering coefficient under simple assumptions (Supplementary information). Sig-
nificant buffering is found in Springer’s gene (P = 2.1×10−15, one-sided Wilcoxon
test). The significantly lower amount of buffering (left, median=0.055) compared
to the genome-wide amount of buffering reported here (right, median=0.148) is
explained by the bias for non-essential and highly expressed genes in Springer and
colleagues experimental setup (median=0.058 for matched distribution, center).
(C) Distribution of buffering coefficient for cis genes (y-axis) by tercile of median
absolute value of gene expression log2-ratio in response to more than 1,500 en-
vironmental changes ([45], x-axis). Environmental expression data were available
for coding genes only.
Chapter 3
Genetic diagnosis of Mendelian
disorders via RNA sequencing
The results presented in this section are part of or adapted from the manuscript
”Genetic diagnosis of Mendelian disorders via RNA sequencing” from Kremer,
Bader et al. 2016 [3]. Supplementary Data are provided in the same order as in
the paper and are located on our webserver1.
Here, we established an analysis pipeline to systematically detect instances of
i) aberrant expression, ii) aberrant splicing, and iii) mono-allelic expression of the
alternative allele to complement whole exome sequencing based genetic diagnosis.
We considered applying our approach on patients diagnosed with a mitochondrial
disorder for three reasons. First, mitochondrial diseases collectively represent one
of the most frequent inborn errors of metabolism affecting 2 in 10,000 individuals
[128]. Second, the broad range of unspecific clinical symptoms and the genetic
diversity in mitochondrial diseases makes molecular diagnosis difficult and WES
often results in variants of unknown significance. As a consequence of the bi-
genomic control of the energy-generating oxidative phosphorylation (OXPHOS)
system, mitochondrial diseases may result from pathogenic mutations of the mi-
tochondrial DNA (mtDNA) or nuclear genome. More than 1,500 different nuclear
genes encode mitochondrial proteins [129] and causal defects have been identified
in approximately 300 genes and presumably more additional disease-associated
genes still awaiting identification [80]. Third, since the diagnosis often relies on
biochemical testing of a tissue sample, fibroblast cell lines are usually available
from those patients. Moreover, for many patients, the disease mechanisms can be
assayed in epidermal fibroblast cell lines even though the disease may manifest
in different tissues [130]. This allows rapid demonstration of the necessary and
sufficient role of candidate variants by perturbation and complementation assays
[68]. This also indicates that disease-causing expression defects, if any, should be
detectable in these cell lines.
We performed RNA-seq on 105 fibroblast cell lines from patients with a sus-
pected mitochondrial disease including 48 patients for which whole exome sequenc-
ing based variant prioritization did not yield a genetic diagnosis (Fig 3.1, Table 3.1,
Methods 4.2.2, Supplementary Data 1). After discarding lowly expressed genes,
1https://i12g-gagneurweb.informatik.tu-muenchen.de/public/paper/
mitoMultiOmics/bioRxiv_2016_12_28/paper_supplement_data/
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RNA-seq identified 12,680 transcribed genes (at least 10 reads in 5% of all sam-
ples, Methods 4.2.4). We systematically prioritized genes with the following three
strategies: i) genes with aberrant expression level [96–98], ii) genes with aberrant
splicing [107, 131], and iii) mono-allelic expression of rare variants [99] to estimate
their disease association (Fig 3.1). All strategies are based on the comparison of
one patient against the rest. We assumed the causal defects to differ between
patients, which is reasonable for mitochondrial disorders with a diversity of 300
known disease-causing genes (Supplementary Data 2). Therefore, the patients
serve as good controls for each other.
Table 3.1: Sample numbers. Number of samples measured with the specified
quantification method binned by their diagnosis status.
Method Diagnosed Not diagnosed Total
RNA 57 48 105
RNA & WES 40 48 88
RNA & proteomics 11 20 31
3.1 Aberrant expression
Before we could assess aberrant expression, we normalized for technical biases,
sex, and biopsy site as follows: Hierarchical clustering revealed three main clus-
ters that could not be linked to biological or technical properties of the samples
(Fig 3.2A). These clusters were considered as groups of unknown technical biases.
We could improve the correlation between replicated samples significantly via cor-
rection for the technical biases (Two-sided Wilcoxon-test P -value 0.02, Fig 3.2B).
Furthermore, 5 HOX genes were among the 150 genes with most variable expres-
sion (3.3% w.r.t. 0.2% HOX genes in all 12,680 genes, Fig 3.2C). HOX genes are
important regulators of the body plan during development of the anterior-posterior
axis [132]. Since the fibroblast cell lines are taken from different body parts de-
pending on the clinic, the first diagnosis and other factors, we hypothesized that
the expression pattern of the HOX genes is a good proxy for the body parts of the
biopsy. To identify likely biopsy site groups we performed hierarchical clustering
of the RNA expression across all samples based only on the HOX genes (identified
as genes with names starting with “HOX”), which revealed four major sample
clusters (Fig 3.2D). After normalization for technical biases, sex, and biopsy site
hierarchical clustering did not reveal further biases (Fig 3.2E, Methods 4.2.5).
The samples typically presented few aberrantly expressed genes (median of 1,
Fig 3.3, Supplementary Table 1) with a large effect (|Z− score| > 3) and sig-
nificant differential expression (Hochberg adjusted P -value < 0.05). Among the
most aberrantly expressed genes across all samples, we found 2 genes encoding
mitochondrial proteins, MGST1 (one case) and TIMMDC1 (two cases) to be sig-
nificantly down-regulated (Fig 3.4). For both genes, WES did not identify any
variants in the respective patients, no variant is reported to be disease-associated,
and no case of potential bi-allelic rare variant is listed in our in-house database
comprising more than 1,200 whole-exomes from mitochondrial patients and 15,000
WES dataset available to us from different ongoing research projects.
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Figure 3.1: Strategy for genetic diagnosis using RNA-seq. The approach
we followed started with RNA sequencing of fibroblasts from unsolved WES pa-
tients. Three strategies to facilitate diagnosis were pursued: Detection of aberrant
expression (e.g. depletion), aberrant splicing (e.g. exon creation) and mono-allelic
expression of the alternative allele (i.e. A as alternative allele). Candidates were
validated by proteomic measurements, lentiviral transduction of the wildtype (wt)
allele or, in particular cases, by specific metabolic supplementation.
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Figure 3.2: RNA normalization. (A) Spearman-correlation heat map of size-
factor normalized gene expression between all fibroblasts (n=119) including biolog-
ical replicates (left side color code). The dendrogram represents the sample-wise
hierarchical clustering. The color code on the top depicts the top three clusters.
The color key of the spearman rho value (top left) includes a histogram based on
the values (green line). (B) Boxplot of the spearman correlation between all repli-
cate pairs (n=35) before and after normalizing for technical variation. Equi-tailed
95% interval (whiskers), 25th, 75th percentile (boxes) and median (bold horizon-
tal line) are indicated. The P -value is based on a two-sided Wilcoxon test. (C)
Boxplot as in (B) of coefficients of variation (standard deviation / mean) for the
30 HOX genes and the remaining genes based on raw gene counts. The P -value is
based on a two-sided Wilcoxon test. (D) Same as (A), but correlation is computed
only on the HOX genes among all samples. The top four clusters are highlighted
(color code top). (E) Same as (A) after normalization for the technical biases, sex
variation and four HOX gene groups.
3.1. ABERRANT EXPRESSION 37
0 20 40 60 80 100
0
1
2
5
10
20
50
100
200
500
Sample rank
A
be
rr
an
tly
 e
xp
re
ss
ed
 g
en
es
Median
90th percentile
Figure 3.3: Overview aberrant expression. Aberrantly expressed genes
(Hochberg corrected P -value < 0.05 and |Z− score| > 3) for each patient fibroblast
cell line.
To evaluate the consequences of diminished RNA expression at the protein
level, we performed quantitative proteomics in a total of 31 fibroblast cell lines
(including these three patients, Table 3.1, Methods 4.2.9, Supplementary Data 3)
from a second aliquot of cells taken at the same time as the RNA-seq aliquot.
Normalized RNA and protein expression levels showed a median rank correlation
of 0.59, comparable to what has been previously reported [95, 133] (App. Fig 6.7).
Patient #73804 showed 2% of control MGST1 level whilst the lack of detection
of TIMMDC1 in both patients (#35791 and #66744) confirmed an even stronger
effect on protein expression, indicating loss of function (Fig 3.5).
MGST1, a microsomal glutathione S-transferase, is involved in the oxidative
stress defense [134]. Accordingly, MGST1 depletion results in significantly in-
creased reactive oxygen species (ROS) levels compared to a healthy individual
(Fig 3.6A, paper methods on ROS). Magnetic resonance images showed also a
progressive brain atrophy for this patient (Fig 3.6B), who suffers from an infantile-
onset neurodegenerative disorder similar to a recently published case with another
defect in the ROS defense system (App. 6.3.2) [135]. Consequently, the loss of
expression of MGST1 is not only a likely cause of the disease of this patient, but
also suggests a treatment with antioxidants.
Both TIMMDC1 patients presented with muscular hypotonia, developmen-
tal delay, and neurological deterioration, which led to death in the first 3 years
of life (App. 6.3.2). Consistent with the described function of TIMMDC1 as a
respiratory chain complex I assembly factor [136, 137], we found isolated com-
plex I deficiency in muscle (Fig 3.7A,B), and globally decreased levels of complex
I subunits in fibroblasts by quantitative proteomics (Fig 3.5) and western blot
(Fig 3.7C). Re-expression of TIMMDC1 in these cells increased complex I sub-
unit levels (Fig 3.7C). These results not only validate TIMMDC1-deficiency as
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Figure 3.4: Examples aberrant expression. (A) Gene-wise RNA expression
volcano plot of nominal P -value s (- log10 P -value ) against Z-scores of the pa-
tient #73804 compared against all other fibroblasts. Absolute Z-scores greater
than 5 are plotted at ±5, respectively. The y-axis is limited to 15, more extreme
values are shown at 15. (B) Same as (a) for patient #35791. (C) Same as (A)
for patient #66744. (D) Sample-wise RNA expression is ranked for the genes
TIMMDC1 (top) and MGST1 (bottom). Samples with aberrant expression for
the corresponding gene are highlighted in red (#35791, #66744, and #73804).
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Figure 3.5: Comparison of RNA and protein changes. (A) Gene-wise com-
parison of RNA and protein fold changes of patient #73804 against all other
fibroblast cell lines. Protein fold changes lower than 0.05 are plotted on the hor-
izontal line. Reliably detected proteins that were not detected in this sample are
shown separately with their corresponding RNA fold changes (points below solid
horizontal line). (B) Same as (A) for patient #35791. Subunits of the mitochon-
drial respiratory chain complex I are highlighted (red squares). (C) Same as (B)
for patient #66744.
disease causing but also provide compelling evidence for an important function of
TIMMDC1 in complex I assembly.
3.2 Aberrant splicing
We identified aberrant splicing events by testing for differential splicing in each
patient against the others, using an annotation-free algorithm able to detect also
novel splice sites (median of 5 abnormal events per sample, Fig 3.8A, Methods
4.2.6). Among the 175 aberrant spliced genes detected in the undiagnosed patients,
the most abundant events were, apart from differential expression of isoforms, exon
skipping followed by the creation of new exons (Fig 3.8B). Two genes encoding
mitochondrial proteins, TIMMDC1 and CLPP, which were among the 20 most
significant genes, caught our attention (Supplementary Table 3).
Out of 136 exon-junction reads overlapping the acceptor site of CLPP exon 6
for patient #58955, 82 (percent spliced in [138] Ψ = 60%) skipped exon 5, and
14 (Ψ = 10%) showed a 3’-truncated exon 5, in striking contrast to other samples
(Fig 3.9A). The likely genetic cause of these two splice defects is a rare homozy-
gous variant in exon 5 of CLPP affecting the last nucleotide of exon 5 (c.661G>A,
p.Glu221Lys 1.2× 10−5 frequency in the ExAC database [74], Fig 3.9B). Both de-
tected splice defects result in truncated CLPP and western blots corroborated the
complete loss of full-length CLPP (Fig 3.9C). Our WES variant filtering reported
this variant as a variant of unknown significance (VUS) and classified CLPP as one
among 30 other potentially bi-allelic affected candidate genes (see Supplementary
Table 1 of [3]). Since the variant was of unknown significance, the patient remained
without genetic diagnosis. The loss of function found by RNA-seq and confirmed
by Western blotting now highlights clinical relevance of the variant within CLPP.
CLPP encodes a mitochondrial ATP-dependent endopeptidase [139] and CLPP-
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Figure 3.6: Details for patient #73804. (A) Quantification of cellular reactive
oxygen species production. Hydroethidine oxidation production was measured
using epifluorescence microscopy. Equi-tailed 95% interval (whiskers), 25th, 75th
percentile (boxes) and median (bold horizontal line) are indicated. The P -value is
based on a two-sided Wilcoxon test. (B) Magnetic resonance imaging of the
brain of patient #73804 at the age of one and two years (left and right panel,
respectively).
deficiency causes Perrault syndrome [140, 141] (OMIM #601119) which is overlap-
ping with the clinical presentation of the patient investigated here including mi-
crocephaly, deafness, and severe psychomotor retardation (App. 6.3.2). Moreover,
a study recently showed that Clpp-/- mice are deficient for complex IV expression
[142], in line with complex IV deficiency of this patient (Fig 3.9D).
Split read distribution indicated that both TIMMDC1-deficient patients ex-
pressed almost exclusively a TIMMDC1 isoform with a new exon in intron 5
(Fig 3.10A). This new exon introduces a frameshift yielding a premature stop
codon (p.Gly199 Thr200ins5*, Fig 3.10B). Moreover, this new exon contained a
rare variant (c.596+2146A>G) not listed in the 1,000 Genomes Project [143, 144].
Whole genome sequencing demonstrated that this variant is homozygous in both
patients (Fig 3.10B,C), the only rare variant in this intron, and close to the splice
site (+6 of the new exon). We could not identify any rare variant in the promoter
region or in any intron-exon boundary of TIMMDC1. Additionally, when testing
six prediction tools for splicing events, this deep intronic rare variant is predicted
by SpliceAid2 [145] to create multiple binding sites for splice enhancers. Together
with the correctly predicted new acceptor and donor sites by SplicePort [146] (Fea-
ture generation algorithm score 0.112 and 1.308, respectively) this emphasizes the
influence of this variant in the creation of the new exon. Besides, the four other
tools predicted no significant change in splicing [147–150].
We further discovered an additional family in our in-house WGS database
(consisting of 36 patients with a suspected mitochondrial disorder and 232 further
patients with unrelated diseases) carrying the same homozygous intronic variant.
In this family three affected siblings presented with similar clinical symptoms al-
though without a diagnosis of a mitochondrial disorder (Fig 3.10C). Two siblings
died before the age of 10. A younger brother (#96687), now 6 years of age,
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Figure 3.7: TIMMDC1 validation. (A) Enzyme activities of respiratory chain
complexes I-V of #35791. Activities were measured in a muscle biopsy and nor-
malized to citrate synthase. (B) Enzyme activities of respiratory chain com-
plexes I-IV of #66744. Analogous to (A). (C-TOP) Western blot of TIMMDC1,
NDUFA13, NDUFB3, and NDUFB8 protein in three fibroblast cell lines with-
out (#62346, #91324, NHDF) and three with a variant in TIMMDC1 (#35791,
#66744, #96687), and fibroblasts re-expressing TIMMDC1 (“-T”) (#35791-T,
#66744-T, #96687-T). UQCRC2 was used as loading control. MW, molecular
weight; CI, complex I subunit; CIII, complex III subunit. (C-BOTTOM) Blue
native PAGE blot of the control fibroblasts re-expressing TIMMDC1 (NHDF-T),
the control fibroblasts (NHDF), patient fibroblasts (#96687), and patient fibrob-
last re-expressing TIMMDC1 (#96687-T). Immunodecoration for complex I and
complex III was performed using NDUFB8 and UQCRC2 antibodies, respectively.
CI, complex I subunit; CIII, complex III subunit.
presented with muscle hypotonia, failure to thrive and neurological impairment
(App. 6.3.2), similar to the patients described above. Western blot analysis con-
firmed TIMMDC1-deficiency (Fig 3.7C) and impaired complex I assembly, which
was restored after re-expression of TIMMDC1 (Fig 3.7C). The discovery of the
same intronic TIMMDC1 variant in three unrelated families from three different
ethnicities provides convincing evidence on the causality of this variant for the
TIMMDC1 loss-of-function.
In almost all non-TIMMDC1-deficiency samples, we noticed a few split reads
supporting inclusion of the new exon (Fig 3.10A), consistent with an earlier report
that many cryptic splice sites are not entirely repressed but active at low levels
[151]. We set out to quantify this phenomenon and to interrogate the frequency of
private exons originating from weakly spliced exons, independent of their possible
association with disease. Consequently, we modeled the distribution of Ψ for the
1,603,042 splicing events detected genome-wide in 105 samples as a mixture of three
components (Methods 4.2.6). The model classified splicing frequencies per splice
site as strong (20%, with Ψ > 5.3%), weak (16%, with 0.16% < Ψ < 5.3%),
or background (64%, with Ψ < 0.16%, Fig 3.11, App. Fig 6.8). Strikingly, the
majority (70%, 4.4-fold more than by chance) of the 17 discovered private exons
originated from weak splice sites (Fig 3.11 bottom). These data confirm that
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Figure 3.8: Aberrant splicing detection. (A) Aberrant splicing events
(Hochberg corrected P -value < 0.05) for all fibroblasts. (B) Aberrant splicing
events (n=175) grouped by their splicing category in undiagnosed patients (n=48)
after manual inspection.
weakly spliced cryptic exons are loci more susceptible to turn into strongly spliced
sites than other intronic regions. These weak splicing events are usually dismissed
as ‘noise’ since they are only supported by few reads in a given sample. Our
analysis shows that they can be detected as accumulation points across multiple
individuals. Hence, these results suggest that the prioritization of deep intronic
variants of unknown significances gained through whole genome sequencing could
be improved by annotating weak splice sites and their resulting cryptic exons.
3.3 Mono-allelic expression
As a third approach, we searched for mono-allelic expression (MAE) of rare vari-
ants. In median per sample, 35,521 heterozygous single nucleotide variant (SNV)s
were detected by WES, of which 7,622 were sufficiently covered by RNA-seq to
call mono-allelic expression (more than 10 reads), 20 showed MAE (Hochberg ad-
justed P -value < 0.05, allele frequency ≥ 0.8), of which 6 were rare variants
(minor allele frequency < 0.001, Methods 4.2.7, Fig 3.12).
Amongst the 18 rare mono-allelic expressed variants in patient #80256 was a
VUS in ALDH18A1 (c.1864C>T, p.Arg622Trp, Fig 3.13A-C), encoding an enzyme
involved in mitochondrial proline metabolism [152]. This VUS had been seen in
WES as compound heterozygous with a nonsense variant (c.1988C>A, p.Ser663*,
Fig 3.13A-C). Variants in ALDH18A1 had been reported to be associated with
cutis laxa III (OMIM #138250) [153, 154], yet the patient did not present cutis
laxa. Because of this inconsistent phenotype and the unknown significance of the
non-synonymous variant, the variants in ALDH18A1 were not regarded as dis-
ease causing. However, RNA-seq-based aberrant expression (Fig 3.13D,E) and
mono-allelic expression analysis prioritized ALDH18A1 again. Our systematically
performed validation by quantitative proteomics revealed severe reduction down to
2% ALDH18A1 (Fig 3.14A), indicating that the rare MAE variant affects transla-
tion or protein stability. Metabolomics profile of blood plasma was in accordance
with a defect in proline metabolism (Fig 3.14B) and the following changes in urea
cycle. Patient fibroblasts showed a growth defect that was rescued by supplementa-
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Figure 3.9: CLPP aberrant splicing. (A) CLPP Sashimi plot of exon skip-
ping and truncation events in affected and unaffected fibroblasts (red and orange,
respectively). The RNA coverage is given as the log10 RPKM-value and the num-
ber of split reads spanning the given intron is indicated on the exon-connecting
lines. At the bottom the gene model of the RefSeq annotation is depicted. The
aberrantly spliced exon is colored in red. (B) Pedigree of the family with mu-
tations in CLPP showing the mutation status. (C) Western Blot showing the
amount of CLPP for the NHDF cell line, the patient carrying variants in CLPP
(#58955), and a patient not carrying variants in CLPP (#74118). α-tubulin was
used as loading control. (D) Enzyme activities of respiratory chain complexes I-V
of #58955. Activities were measured in a muscle biopsy and normalized to citrate
synthase.
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Figure 3.10: TIMMDC1 aberrant splicing. (A) TIMMDC1 Sashimi plot of
exon creation events in affected and unaffected fibroblasts (red and orange, re-
spectively). The RNA coverage is given as the log10 RPKM-value and the number
of split reads spanning the given intron is indicated on the exon-connecting lines.
At the bottom the newly created exon is depicted in red within the RefSeq anno-
tation track. (B) Coverage tracks (light red) for patients #35791, #66744, and
#91324 based on RNA and whole genome sequencing. For patient #91324 only
WGS is available. The homozygous SNV c.596+2146A>G is present in all cov-
erage tracks (vertical orange bar). The top tracks show the genomic annotation:
genomic position on chromosome 3, DNA sequence, amino acid translation (grey,
stop codon in red), the RefSeq gene model (blue line), the predominant additional
exon of TIMMDC1 (blue rectangle), and the SNV annotation of the 1000 Genomes
Project (each black bar represents one variant). (C) Pedigrees of the families with
mutations in TIMMDC1 showing the mutation status. Mutations are confirmed
by Sanger sequencing.
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Figure 3.11: Weak splicing. Percent spliced in (Ψ) distribution for different
splicing classes and genes. Top: Histogram giving the genome-wide distribution
of the 3’ and 5’ Ψ-values based on all reads over all samples. Middle: The shaded
horizontal bars represent the densities (black for high density) of the background,
weak and strong splicing class, respectively (Methods 4.2.6). Bottom: Ψ-values of
the predominant donor and acceptor splice sites of genes with private splice sites
(i.e. found dominant in at most two samples) computed over all other samples.
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Figure 3.12: Distribution of heterozygous single nucleotide variants
(SNVs) across samples for different consecutive filtering steps. Het-
erozygous SNVs detected by exome sequencing (black), SNVs with RNA-seq cov-
erage of at least 10 reads (gray), SNVs where the alternative allele is mono-
allelically expressed (alternative allele frequency ≥ 0.8 and Benjamini-Hochberg
corrected P -value < 0.05, blue), and the rare subset of those (ExAC minor allele
frequency < 0.001, red).
tion of proline, validating impaired proline metabolism as the underlying molecular
cause (Fig 3.14C). Our experimental evidence strongly suggests that the two ob-
served variants are causal. Moreover, a recent report [155] on ALDH18A1 patients
extended the phenotypic spectrum to spastic paraplegia (OMIM #138250), which
resembles the symptoms of our patient (App. 6.3.2).
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Figure 3.13: Mono-allelic expression of ALDH18A1. (A) Pedigree of the
family with mutations in ALDH18A1 showing the mutation status. Mutations are
confirmed by Sanger sequencing. (B) Fold change between alternative (ALT+1)
and reference (REF+1) allele read counts for the patient #80256 compared to total
read counts per SNV within the sample. Points are colored according to the groups
defined in Fig 3.12. (C) Exome and RNA sequencing read coverage tracks (gray) of
the two SNVs indicated in (B) for ALDH18A1 (antisense strand). Alternative (Alt)
and reference (Ref) nucleotides are indicated by their corresponding color (A green,
G brown, T red). (D) Gene-wise RNA expression volcano plot of nominal P -value s
(-log10 P -value ) against Z-scores of the patient #80256 compared against all other
fibroblasts. Absolute Z-scores greater than 5 are plotted at ±5, respectively. The
y-axis is limited to 15, more extreme values are shown at 15. (E) Sample-wise
RNA expression is ranked for ALDH18A1. Samples with aberrant expression for
the corresponding gene are highlighted in red (#80256).
In another patient (#62346) we found borderline non-significant low expression of
MCOLN1 (Fig 3.15A,B) with 10 of 11 reads expressing an intronic VUS (c.681-
19A>C, Fig 3.15C). This intronic variant was detected as part of a retained intron,
which introduced a nonsense codon (p. Lys227 Leu228ins16*, Fig 3.15D). When
looking at the WES data we could additionally identify a heterozygous nonsense
variant (c.832C>T, p.Gln278*, Fig 3.15E). The allele with the exonic nonsense
mutation was not expressed, most likely due to nonsense-mediated decay. Mu-
tations in MCOLN1 are associated with mucolipidosis (OMIM #605248). The
symptoms of the patient were initially suggestive for mucolipidosis, but none of
the enzymatic tests available for mucolipidosis type 1, 2, and 3 revealed an enzyme
deficiency in blood leukocytes (App. 6.3.2). Moreover, MCOLN1 was missed by
our WES variant filter since the intronic variant was not prioritized. Hence, the
WES data could not be conclusive about MCOLN1. In contrast, the RNA-seq
data demonstrated two loss-of-function alleles in MCOLN1 and therefore estab-
lished the genetic diagnosis.
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Figure 3.14: Proline rescue for patient #80256. (A) Gene-wise comparison
of RNA and protein fold changes of the patient #80256 against all other patients’
fibroblasts. The position of the gene ALDH18A1 is highlighted. Reliably detected
proteins that were not detected in this sample are shown separately with their
corresponding RNA fold changes (points below solid horizontal line). (B) Rela-
tive intensity for metabolites of the proline biosynthesis pathway (inlet) for the
patient #80256 and 16 healthy controls of matching age. Equi-tailed 95% inter-
val (whiskers), 25th, 75th percentile (boxes) and median (bold horizontal line)
are indicated. Data points belonging to the patient are highlighted (red circles,
P -value s are computed with Student’s t-test). (C) Cell counts under different
growth conditions for the normal human dermal fibroblast (NHDF) and patient
#80256. Both fibroblasts were grown in fetal bovine serum (FBS), dialyzed FBS
(without proline) and dialyzed FBS with proline added. Boxplot as in (a). P -
value s are based on a two-sided Wilcoxon test.
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Figure 3.15: Mono-allelic expression of MCOLN1. (A) Gene-wise RNA
expression volcano plot of nominal P -value s (-log10 P -value ) against Z-scores
of the patient #62346 compared against all other fibroblasts. Absolute Z-scores
greater than 5 are plotted at ±5, respectively. (B) Sample-wise RNA expression is
ranked for MCOLN1. Samples with aberrant expression for the corresponding gene
are highlighted in red (#62346). (C) Fold change between alternative (ALT+1)
and reference (REF+1) allele read counts for the patient #62346 compared to
total read counts per SNV within the sample. Points are colored according to the
steps of the mono-allelic expression variant filter cascade. (D) Intron retention
for MCOLN1 in patient #62346. Tracks from top to bottom: genomic position on
chromosome 19, amino acid translation (red for stop codons), RefSeq gene model,
coverage of whole exome sequencing of patient #62346, RNA-seq based coverage
for patients #62346 and #85153 (red and orange shading, respectively). SNVs are
indicated by non-reference colored bars with respect to the corresponding reference
and alternative nucleotide. (E) Pedigree of the family with mutations in MCOLN1
showing the mutation status.
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Chapter 4
Methods
4.1 Methods for the chapter on negative feed-
back
This section explains the methods used to generate the results presented in chap-
ter 2. The following methods are additionally described in the paper [1]: Data
availability, Yeast strains, DNA sequencing, Transcriptome profiling.
The methods presented in this section are part of the manuscript ”Negative
feedback buffers effect of regulatory variants” from Bader et al. 2015 [1].
4.1.1 Genotyping and allele frequencies
S96 is isogenic to S288c besides the mating type and therefore we could use the
reference genome of the S. cerevisiae database [111]. We used the allele frequencies
computed earlier by [116]. The coverage of the spore pool B DNA sample was
lower than for the other three samples (see DNA sequencing section), hence we
have allele frequencies for about 60,000 and 10,000 SNPs, respectively. To adjust
the SNP coordinates we lifted them from S288c version R63 to R64. We smoothed
the allele frequencies over a window of 28,000bp (∼ 10 Centimorgan) using local
binomial likelihood estimation (R CRAN package locfit). We observed a mapping
bias towards the S288c genome (median S288c allele frequency 0.52), most likely
due to the better annotated reference genome. This artificial bias was used to
correct the spore frequency estimations. Those mapping-bias-corrected spore allele
frequencies were used to correct the read counts for the statistical model. A similar
mapping issue was not observed for the hybrid RNA counts.
4.1.2 Gene annotation
To include also recent non-coding RNAs we used the gene annotation of Xu and
colleagues [117] for gene coordinates in the S96 strain (isogenic to S288c). The
SK1 gene annotation was generated via bidirectional best hits: Using the coor-
dinates from Xu and colleagues we extracted the S96 gene sequences from the
S288c genome version R64 of the Saccharomyces Genome Database [111]. These
sequences were searched in the SK1 genome using BLAST [156] with default pa-
rameters. The best hit of this first search became query of the second search in the
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S96 genome. If this second search resulted in the query of the first, we considered
the gene pair as ortholog candidates. Every pair with an alignment identity of
more than 95% was considered orthologous. This includes also longer indels and
does not restrict our analysis to single nucleotide variants.
Additionally, expression levels for each gene are defined as the average read counts
divided by the mean gene length over both strains. These levels were sorted and
categorized into three equally sized groups: Low, Middle and High using cut2 (R
package Hmisc). Transcription factor annotation was taken from [157].
4.1.3 Mapping and read counts
RNA-seq reads were mapped to the both genomes of S96 and SK1 jointly. GSNAP
[158] was used allowing for four mismatches with novel splice site detection enabled,
apart from that we used default parameters. We classified mapped read pairs into
three categories: common, only SK1, only S96. Common reads matched equally
well to both genomes and therefore are not apt to measure ADE. Only the strain
specific and proper-paired alignments can led to ADE and were filtered by their
SAM flags (i.e. 83/163 and 99/147) for our statistical model. Additionally, if
one read had one proper pair and one mate aligned to the same chromosome on
the other allele, it was considered as specific, too. All other reads were discarded
together with the common reads.
The filtered alignments were processed with htseq-count [159] using intersection-
strict as overlap mode to generate read counts per gene. Strict means that a
read or read pair has to align completely inside the annotated gene region to be
counted. As gene annotation we used our expressed orthologs with start and end
extended by 50bp to increase sensitivity.
4.1.4 Statistical modeling of cis and local trans effects
The raw counts of reads (integer values) per annotated gene are prone to systematic
biases that need to be corrected. During the growth of the spores artificial (one
mating type) and natural selection takes place [114, 115]. To deal with this bias,
we used the genomic allele frequencies of the spores for correction (Supplementary
Fig 2.3, see genotyping and allele frequencies section). Additionally, we corrected
for length differences between the strains gene-wise as well as the standard sample
size factors by DESeq2 [36]. Furthermore, we modelled additional confounding
factors for diploid cells, and the biological replicate of each hybrid and spore pool
(design matrix, Table 4.1). Hence, allele-specific read counts Ki,j were modelled
according to the following generalized linear model:
Ki,j ∼ NB(µi,j, αi) (4.1)
µi,j = sj × fi,j × qi,j × li (4.2)
log2(qi,j) = β
0
i + β
cis
i x
cis
i,j + β
localtrans
i x
localtrans
i,j + β
nuis
i
T
xnuisi,j (4.3)
where NB is the negative binomial distribution, αi is a gene-specific dispersion
parameter; sj is the size factor of sample j; fi,j is the allele frequency of gene i in
sample j ; li is the length difference for the orthologous gene pair i. This value is
4.1. METHODS FOR THE CHAPTER ON NEGATIVE FEEDBACK 55
Table 4.1: DESeq design matrix. A cell denotes whether we can observe an effect
of the modelled factor (column) in the specified sample (row). Samples split by
strain and biological replicate.
SAMPLE \ FACTOR cis local trans diploid hybrid B spore B
hybrid A only SK1 1 1 1 0 0
hybrid A only S96 0 1 1 0 0
hybrid B only SK1 1 1 1 1 0
hybrid B only S96 0 1 1 1 0
spore A only SK1 1 1 0 0 0
spore A only S96 0 0 0 0 0
spore B only SK1 1 1 0 0 1
spore B only S96 0 0 0 0 1
0.5 in the hybrid sample and is robustly estimated from genomic DNA sequencing
in the pool. xcisi,j is 1 for allele K and 0 otherwise. x
localtrans
i,j is 1 in the pool
for allele K and 0 otherwise. xnuisi,j represents all nuisance parameters to control
for: diploid, hybrid B, pool B (Table 4.1). The model was implemented with the
R/Bioconductor package DESeq2 [36], which provides robust estimation of the size
factors and of the dispersion parameters.
After the correction and fitting process we removed genes from further analysis
that had less than ten reads average count over all samples, in order to increase
our detection power at the same type I error (Supplementary Fig 2.4 top row,
[36, 160]). This minimal expression filtering resulted in 6,691 genes. Accordingly,
we corrected the P -values for multiple testing using false discovery rate [161].
Supplementary table 1 provides normalized counts together with fitted coefficients
and further gene annotation.
4.1.5 Analysis of ribosome profiling data
We re-analyzed read count data kindly provided by Carlo Artieri and Hunter Fraser
(personal communication, supplementary table 2), adopting our model to the hy-
brid data from RNA-seq and ribosomal profiling. The ribosome-bound fraction
was assumed to be the product of the expression level and the binding affinity
to RNA, a proxy for translation efficiency [162]. Accordingly, allele specific read
counts Ki,j were modelled according to the following generalized linear model:
Ki,j ∼ NB(µi,j, αi) (4.4)
µi,j = sj × qi,j (4.5)
log2(qi,j) = β
0
i + β
cisRNA
i x
cisRNA
i,j + β
cisTE
i x
cisTE
i,j + β
nuis
i
T
xnuisi,j (4.6)
where NB is the negative binomial distribution, αi is a gene-specific dispersion
parameter; sj is the size factor of sample j; x
cisRNA
i,j is 1 for the S. paradoxus allele
and 0 otherwise. xcisTEi,j is 1 in the ribosome-bound fraction for the S. paradoxus
allele and 0 otherwise. xnuisi,j represents nuisance parameters that were controlled
for: baseline translation efficiency and overall replicate effect (Table 4.2). The
model was implemented with the R/Bioconductor package DESeq2 [36]. Supple-
mentary table 3 provides normalized counts together with fitted coefficients and
further gene annotation.
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Table 4.2: DESeq design matrix for ribosome profiling data. Value of covariates
by sample for the Equation 4.4.
SAMPLE RNA cis TE cis RNA bias hybrid rep2
hybrid RNA 1 SCER 1 0 1 0
hybrid RNA 2 SCER 1 0 1 1
hybrid RNA 1 SPAR 0 0 1 0
hybrid RNA 2 SPAR 0 0 1 1
hybrid RIBO 1 SCER 1 1 0 0
hybrid RIBO 2 SCER 1 1 0 1
hybrid RIBO 1 SPAR 0 0 0 0
hybrid RIBO 2 SPAR 0 0 0 1
4.1.6 Improvements on the original analyses of ribosomal
profiling data
We improved the assessment of translational buffering compared to the original
studies [51, 52] in the following three aspects:
1. Modeling the biological variance. In the two original studies, tests for
allelic differential expression were performed for each biological replicate sep-
arately. One of these tests is a binomial test [49] and the other one is a more
conservative test controlling for differences in mappability and nucleotide
content [118]. To call significant effects over the two biological replicates,
the largest P -value of the two samples had to be smaller than a threshold
and allelic expression imbalance had to agree in direction. Hence, both of
these approaches assess the within-sample significance but do not assess the
significance of allelic expression ratios compared to the variability of expres-
sion levels between biological replicates. We found that allelic expression
ratios for genes called significant according to these procedures often had
low fold-changes in comparison to the median biological standard deviation
(20.2% less than 1.96 times the median standard deviation at a nominal P -
value of 0.05 for [51], Supplementary Fig 6.5), indicating that the extent
of many reported effects did not significantly replicate between biological
replicates. As comparison, assuming known variance, Gaussian distribution,
and same sample size (n = 2), a nominal P -value of 0.05 is reached for
differences of about 1.96 or more standard deviations. With our test, which
models both the so-called shot noise (Poisson noise dominating low counts)
and the biological noise (dominating the high counts), only 3.1% of the called
genes at a nominal P -value of 0.05 show less than 1.96 times the median
standard deviation (Supplementary Fig 6.5). Consequently, P -value s were
underestimated with the original statistical tests leading to an abundant
fraction of rejected null hypotheses. The same issue affected the significance
assessment of translation efficencies.
2. Independent estimates. Both studies estimated translational efficiencies
as the ratio of RNA levels in the ribosome-bound fraction divided by the
RNA expression level. Hence, estimates for translational efficiencies and for
expression levels were not independent. Specifically, noise in RNA expres-
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sion level measurements induce anticorrelation between translation efficiency
estimates and expression level estimates. A scatterplot of allelic log-ratios
of translation efficiencies versus allelic log-ratios of RNA levels gave the mis-
leading impression that the two quantities are biologically anticorrelated (Fig
3B in [52] and Fig 2A in [51]). In contrast, scatterplot of the untransformed
data does not indicate a trend for translational buffering (mass of the data
above diagonal, Fig 2.8B). Because the original statistical tests did not as-
sess the between-replicate variability, most of the effects that were called
significant for allelic differences in expression and in translation efficiency
were likely due to random variations. Estimated allelic ratio of expression
and translation efficiencies of these genes therefore tended to suffer from the
anti-correlation and thus to spuriously show opposite effects. Re-analysing
the data of [51] with our test and with filtering criteria matching those of
the original analysis (FDR=0.05 and no cut-off on fold change), we found
much fewer instances (99) significant for both translation efficiency and cis
effects. Among these 99 genes, only 55 (56%) show opposing effects which is
not statistically significant (P = 0.31, two-sided binomial test).
3. Considering noise in explanatory variable. In one of the two original
studies, genome-wide trend for compensation at the translational level was
estimated by a regression of allelic ratios in the ribosome-bound fraction
over the allelic expression ratios [51]. An important assumption of linear
regression is that there is no noise in the explanatory variable. This was not
the case here because the RNA levels are noisy estimates. Linear regression
in case of noise in the explanatory variable is known to underestimate the
slope (regression to the mean effect), which had led to underestimation of
the trend. Compare Fig 2B in (Artieri2014) with supplementary figure 2.8,
here we are instead using principal component analysis.
The two latter points were also noticed by [126].
4.1.7 Buffering coefficient
Here we define a measure to quantify the amount of buffering on gene expres-
sion. We show that under some assumptions our measure is the same than the
compensation metric C of [127].
We write a gene expression level y as :
y = α1−CβC (4.7)
where C is the coefficient of compensation, α is the expression level that the gene
would reach in the absence of compensation (i.e. if C = 0), β is the expression
level that would be reached under full compensation (C = 1).
Estimation of C in this study
We assume the unlogged expression level of an allele to be the product of cis
and trans effects: y = cis × trans. Moreover, we assume the cis effect to be
independent of the compensation C. Thus the allele expression ratio in the hybrid
58 CHAPTER 4. METHODS
is independent of C and is the same as in absence of compensation:
yHYBRIDB
yHYBRIDA
=
cisB
cisA
=
αB
αA
(4.8)
In the spores carrying allele A or allele B, respectively, the level of expressions are:
ySPOREA = α
1−C
A β
C (4.9)
ySPOREB = α
1−C
B β
C (4.10)
Hence the allelic expression ratio in the pool of spores is:
ySPOREB
ySPOREA
=
(
αB
αA
)1−C
=
(
yHYBRIDB
yHYBRIDA
)1−C
(4.11)
(4.12)
We therefore use as working definition of the coefficient of compensation C in this
study:
C = 1− log2(y
SPORE
B /y
SPORE
A )
log2(y
HYBRID
B /y
HYBRID
A )
(4.13)
(4.14)
Definition
To quantitatively estimate how much cis effects are buffered by local trans effects,
we defined the buffering coefficient C as:
C = 1−
log(y
spore, SK1
/y
spore, S96
)
log(y
hybrid, SK1
/y
hybrid, S96
)
(4.15)
where y denotes the RNA expression level.
In order to estimate buffering at the transcriptional level, we also defined buffering
coefficient when comparing ribosome profiling data (RP) and RNA levels in the
S. par. x S. cer. cross.
Ctranslation = 1−
log(y
RP, S. par.
/y
RP, S. cer.
)
log(y
RNA, S. par.
/y
RNA, S. cer.
)
(4.16)
where y
RNA
denotes the RNA expression level, and y
RP
the ribosome occupancy.
Note that both for the local trans regulation case and for the translation efficiency
case, C is ill-defined for hybrid RNA ratios close to zero. This is equivalent to
say that buffering can only be assessed if there is a cis effect in the first place.
We therefore restricted the analysis of buffering for genes with significant and
sufficiently large cis effects.
Calibration
We defined as raw buffering coefficient the quantity:
Craw = 1−
log(#reads
spore, SK1
/#reads
spore, S96
)
log(#reads
hybrid, SK1
/#reads
hybrid, S96
)
(4.17)
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Craw is a biased estimator of the buffering coefficient C defined by Equation 4.15.
We empirically derived an unbiased estimator of C by inferring the relationship
between Craw and C from simulations for all values of C in [0, 0.5] with a 0.005
spacing. For each simulated value of C, read counts for every gene i were simulated
by random draws according to Equations (1-3), keeping all the parameters fixed
to their estimated values on the primary dataset, except for substituting β localtransi
with −Cβcisi . On these simulated genome-wide read counts, the exact same analy-
sis as for the primary dataset was performed (i.e. including filter for minium read
counts, DESeq2 normalization and fits, and filter for large and significant cis ef-
fects) and the median Craw across cis genes was computed. To obtain an unbiased
estimator of translational buffering for the ribosome dataset, the same procedure
was applied substituting βcisTE with −CβcisRNA. For both datasets, we observed
a linear relationship between the simulated true C and the median Craw (Supple-
mentary Fig 6.6A-B, Pearson correlation ¿0.99) and used the linear regression fit
as calibration function. This linear transformation of Craw was then used for all
further analysis as buffering coefficient C.
Significance
To assess the significance of the median buffering coefficient, data were simulated
under the null hypothesis of independence between cis effects and local trans ef-
fects in a semi-parametric fashion. A total of B = 1000 bootstrap genome-wide
datasets were generated by permuting the estimated local trans effects β localtransi
between genes while keeping all remaining parameters fixed to their estimated
values on the primary dataset and drawing counts according to Equations (1-3).
On these simulated genome-wide read counts, the exact same analysis as for the
primary dataset was performed (i.e. including filter for minium read counts, DE-
Seq2 normalization and fits, and filter for large and significant cis effects) and the
median buffering coefficient across cis genes was computed.
One-sided P -value was then estimated by [163]:
P =
1 + #{C̄∗i ≥ C̄}
B + 1
(4.18)
where C̄ is the median buffering coefficient in the observed dataset and C̄∗i , i =
1 . . . B are the bootstrap values of the median buffering coefficient (Supplemen-
tary Fig 6.6C). The same procedure was applied to the ribosome dataset whereby
the estimated translation efficiency estimates βcisTEi were permuted across genes
(Supplementary Fig 6.6D).
4.1.8 Comparison with Springer’s C
Comparison with Springer et al. [127] data was done for the same growth medium
as the one used in this study (rich growth medium YPD). Distribution of our
buffering coefficient under matching distribution of gene category and expression
levels (Fig 2.10A, central box) was obtained by (i) restricting to non-essential
genes and (ii) randomly sampling 1,000 times with replacement the same number
of genes in each tercile of expression as in Springer and colleagues’ dataset.
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4.1.9 Equivalence with Springer’s C
Springer and colleagues [127] assess buffering of a protein’s expression using diploid
strains in which one of the two alleles is marked by GFP. In the so-called wild type
strain, the unmarked allele is kept intact whereas in the heterozygote strain the
unmarked allele is deleted. Springer’s compensation metric is defined as the log2-
ratio of the GFP expression in the heterozygote over the wild type strain.
We index with A the unmarked allele’s constants and with B the GFP-tagged
allele’s constants. In this experiment, the expression levels of the two alleles are
assumed to be the same in absence of compensation (i.e. αA = αB := α/2) and in
presence of compensation (yA = yB). The feedback acts on the overall expression
level y := yA + yB = 2yB.
According to Equation 4.7, we expect the GFP expression level yWTB to be:
yWTB =
1
2
y =
1
2
α1−CβC (4.19)
The GFP expression level in the heterozygote strain, for which yA = 0, is:
yHETB = y = (α/2)
1−CβC (4.20)
Hence we get:
log2
(
yHETB
yWTB
)
= log2
(
(1/2)1−C
1/2
)
= C (4.21)
4.2. METHODS FOR THE CHAPTER ON GENETIC DIAGNOSIS 61
4.2 Methods for the chapter on genetic diagnosis
This section explains the methods used to generate the results presented in chap-
ter 3. Where the Author contributions information of the paper [3] is not de-
tailed enough, I gave further explanations at the beginning of the corresponding
method’s section. The following methods are additionally described in the paper
[3]: Sanger sequencing, exome sequencing, whole genome sequencing, cell culture,
mass spectrometric sample preparation, mass spectrometric data acquisition, Im-
munoblotting, Blue native PAGE, metabolomics, Proline supplementation growth
assay, Cellular reactive oxygen species production.
The methods presented in this section are part of the manuscript ”Genetic diagnosis
of Mendelian disorders via RNA sequencing” from Kremer, Bader et al. 2016 [3].
4.2.1 Variant of unknown significance
“A variation in a genetic sequence whose association with disease risk is
unknown. Also called unclassified variant, variant of uncertain signifi-
cance, and VUS.” (see https://www.cancer.gov/publications/dictionaries/
genetics-dictionary?cdrid=556493 )
4.2.2 Exome alignment and variant prioritization
Read alignment to the human reference genome (UCSC Genome Browser build
hg19) was done using Burrows-Wheeler Aligner (v.0.7.5a)[164]. Single-nucleotide
variants and small insertions and deletions (indels) were detected with SAMtools
(version 0.1.19)[165, 166]. Variants with a quality score below 90, a genotype
quality below 90, a mapping quality below 30, and a read coverage below 10
were discarded. The reported variants and small indels were annotated with the
most severe entry by the Variant Effector Predictor [167] based on The Sequence
Ontology term ranking [168]. The candidate variants for one patient are filtered
to be rare, affect the protein sequence and potentially both alleles. Variants are
rare with a minor allele frequency < 0.001 within the ExAC database [74] and a
frequency < 0.05 among our samples. Variants affect the protein, if they are a
coding structural variant or their mutation type is one of ablation, deletion, frame-
shift, incomplete, start lost, insertion, missense, splice, stop gain, stop retain,
unstart, unstop. A potential biallelic effect can be caused by either a homozygous
or at least two heterozygous variants in the same gene, whereas in latter case we
assume that the heterozygous variants are on different alleles (Appendix Fig 6.9).
This filter is designed for a recessive type disease model and does not account for
a single heterozygous variant that could be disease-causing in a dominant way.
4.2.3 RNA sequencing
Non-strand specific, polyA-enriched RNA sequencing was performed as described
earlier [130]. Briefly, RNA was isolated from whole-cell lysates using the All-
Prep RNA Kit (Qiagen) and RNA integrity number (RIN) was determined with
the Agilent 2100 BioAnalyzer (RNA 6000 Nano Kit, Agilent). For library prepa-
ration, 1 µg of RNA was poly(A) selected, fragmented, and reverse transcribed
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with the Elute, Prime, Fragment Mix (Illumina). End repair, A-tailing, adaptor
ligation, and library enrichment were performed as described in the Low Through-
put protocol of the TruSeq RNA Sample Prep Guide (Illumina). RNA libraries
were assessed for quality and quantity with the Agilent 2100 BioAnalyzer and the
Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies). RNA libraries were
sequenced as 100 bp paired-end runs on an Illumina HiSeq2500 platform.
4.2.4 Processing of RNA sequencing files
RNA-seq reads were demultiplexed and mapped with STAR (version 2.4.2a)[169]
to the hg19 genome assembly (UCSC Genome Browser build). In addition to
the default parameters we detected gene fusions and increased sensitivity for
novel splice junctions (chimSegmentMin=20, twopassMode=”Basic”). Analy-
sis was restricted to the 27,682 UCSC Known Genes (genome annotation ver-
sion hg19)[170] of chromosomes 1 to 22, M, X, or Y. Per gene, reads that are
paired with mates from opposite strands and that overlapped completely within
the gene on either strand orientation were counted using the summarizeOver-
laps function of the R/Bioconductor GenomicAlignments [171] package (param-
eters: mode=intersectionStrict, singleEnd=FALSE, ignore.strand=TRUE, frag-
ments=FALSE). If the 95th percentile of the coverage across all samples was be-
low 10 reads the gene was considered “not expressed” and discarded from later
analysis.
4.2.5 Computing RNA fold changes and differential ex-
pression
Before testing for differential expression between one patient of interest and all
others, we controlled for technical batch effect, sex, and biopsy site as inferred
from the expression of hox genes (Supplementary Data 4). We modeled the RNA-
seq read counts Ki,j of gene i in sample j with a generalized linear model using the
R/Bioconductor DESeq2 package [36, 37]:
Ki,j ∼ NB(sj × qi,j, αi) (4.22)
log2(qi,j) = β
0
i + β
condition
i x
condition
i,j + β
batch
i x
batch
i,j + β
sex
i x
sex
i,j + β
hox
i x
hox
i,j (4.23)
Where NB is the negative binomial distribution; αi is a gene specific dispersion
parameter; sj is the size factor of sample j; β
0
i is the intercept parameter for gene
i. The value of xconditioni,j is 1 for all RNA samples j of the patient of interest,
thereby allowing for biological replicates, and 0 otherwise. The resulting vector
βconditioni represents the log2-fold changes for one patient against all others. Z-
scores were computed by dividing the fold changes by the standard deviation of
the normalized expression level of the respective gene. The P -value s corresponding
to the βconditioni were corrected for multiple testing using the Hochberg family-wise
error rate method [172].
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4.2.6 Detection of aberrant splicing
The methods presented in this section were developed by Christian Mertes,
co-author of [3].
The LeafCutter [173] software was utilized to detect aberrant splicing. Each
patient was tested against all others. To adjust LeafCutter to the rare dis-
ease setting, we modified the parameters to detect rare clusters, capture local
gene fusion events and to detect junctions unique to a patient (minclureads=30;
maxintronlen=500,000; mincluratio=1e-5, Supplementary Data 4). Furthermore,
one sample was tested against all other samples (min samples per group=1;
min samples per intron=1). The resulting P -value s were corrected for multiple
testing using a family-wise error rate approach [172].
The significant splice events (Hochberg adjusted P-value < 0.05) detected in the
undiagnosed patients were visually classified as exon skipping, exon truncation,
exon elongation, new exon, complex splicing (any other splicing event or a combi-
nation of the aforementioned ones) and false positives (n=73, Fig 3.8). However,
due to LeafCutter’s restriction to split reads it is difficult to detect intron retention
events, since in a perfect intron retention scenario no split-reads are present.
For further analysis, only reads spanning a splice junction, so called split reads,
were extracted with a mapping quality of greater than 10 to reduce the false
positive rate due to mapping issues. Each splice site was annotated as belonging
to the start or end of a known exon or to be entirely new. For the reference
exon annotation the GENCODE release 24 based on GRCh37 was used [174]. The
percent spliced in (Ψ) values for the 3’ and 5’ sites were calculated as described
earlier [138]:
Ψ5(D,A) =
n(D,A)∑
A′ n(D,A
′)
and Ψ3(D,A) =
n(D′, A)∑
D′ n(D
′, A)
(4.24)
Where D is a donor site and A is an acceptor site. n(D,A) denotes the number
of reads spanning the given junction. D′ and A′ represent all possible donor and
acceptor sites, respectively.
Classification of splice sites into background, weak and strong was done by mod-
eling the distribution of the Ψ5 and Ψ3-values with three components. Identi-
fiability of the three components was facilitated by considering three groups of
junctions depending on previous annotation of splice sites: ‘no side is annotated’,
‘one side is annotated’ and ‘both sides are annotated’. Specifically, the number
of split reads n(D,A) of a junction conditioned on the total number of reads
N(D,A) =
∑
A′ n(D,A
′) , for Ψ5, and N(D,A) =
∑
D′ n(D
′, A) , for Ψ3, was
modeled as:
P (n(D,A)|N(D,A)) =
∑
c∈{bg,wk,st}
∑
s∈{0,1,2}
πs,cBetaBin(n(D,A)|N(D,A), αc, βc)
(4.25)
where c is the component index, s the number of annotated sites and BetaBin the
beta-binomial distribution. Hence, the components were modeled to have the same
parameters αc, βc in all three groups but their mixing proportions πs,c to be group-
specific. Fitting was performed using the expectation-maximization algorithm. For
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the initial step, the data points were classified as background (Ψ < 0.001), weak
spliced (Ψ < 0.1) and canonical (Ψ ≥ 0.1). After convergence of the clustering the
obtained parameters were used to estimate the probability for each junction side
to belong to a given class.
4.2.7 Detection of mono-allelic expression
The methods presented in this section were developed jointly by Christian Mertes,
co-author of [3] and Daniel M Bader.
For mono-allelic expression analysis only heterozygous single nucleotide variants
with only one alternative allele detected from exome sequencing data were used.
The same quality filters were used as mentioned in the exome sequencing part, but
no frequency filter was applied. To get allele counts from RNA sequencing for the
remaining variants the function pileLettersAt from the R/Bioconductor package
GenomicAlignments [171] was used. The data was further filtered for variants
with coverage of at least 10 reads on the transcriptome.
The DESeq2 package [36, 37] was applied on the final variant set to estimate the sig-
nificance of the allele-specific expression. Allele-specific expression was estimated
on each heterozygous variant independently of others (i.e. without phasing the
variants). For each sample, a generalized linear model was fitted with the contrast
of the coverage of one allele against the coverage of the other alleles (condition).
Specifically, we modeled Ki,j the number of reads of variant i in sample j as:
Ki,j ∼ NB(sj × qi,j, α) (4.26)
log2(qi,j) = β
0
i + β
condition
i x
condition
i,j (4.27)
Where NB is the negative binomial distribution; the dispersion parameter α was
fixed for all variants to α = 0.05, which is approximately the average dispersion
over all samples based on the gene-wise analysis; sj is the size factor of each
condition; β0i is the intercept parameter for variant i. The value of x
c
i,jondition
is 1 for the alternative alleles and 0 otherwise. The resulting βconditioni represents
the log2-fold changes for the alternative allele against the reference allele. The
independent filtering by DESeq2 was disabled (independentF iltering = FALSE)
to keep the coverage outliers among the results. To classify a variant as mono-
allelically expressed a cutoff of |βconditioni | ≥ 2 was used, which corresponds to an
allele frequency ≥ 0.8, and we filtered Hochberg adjusted P -value s to be smaller
than 0.05.
4.2.8 Processing of proteome intensities
Label-free protein quantification was done using the MaxLFQ algorithm [175] in-
tegrated into MaxQuant (for detailed parameters see [3]).
The LFQ intensities and gene names were extracted for 6,566 protein groups from
the MaxQuant output file proteinGroups.txt. For protein groups with more than
one member, the first member was chosen to represent the group as single protein
with a distinct gene name (similar to earlier studies [176]). MaxLFQ intensities of
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0 actually represent non-quantified peaks and were therefore replaced with miss-
ing values (NA). The 10 samples that had a frequency of missing values higher
than 50% were considered bad quality and were discarded. Furthermore, proteins
were discarded because they had no gene name assigned (n=198), were not the
most abundant among their duplicates (n=295), were not expressed in any sample
(n=93), because their 95th percentile was not detected (n=549), which was also
considered as not expressed, analogously to RNA filtering. Finally, 5,431 proteins
and 31 samples were considered for further analysis (Supplementary Data 3).
4.2.9 Computing protein fold changes and differential ex-
pression
Since the mass spectrometric measurements of all samples were done in a single
run, no technical artifacts could be found with a hierarchical clustering. Protein
differential expression for each patient compared to the others was tested using
moderated T-test approach as implemented in the R/Bioconductor limma package
[177]. The transcriptome covariates for sex and HOX effects were used in the linear
model for normalization.
4.2.10 Transduction and Transfection
Overexpression of TIMMDC1 in fibroblast cell lines was performed by lentivirus-
mediated expression of the full-length TIMMDC1 cDNA (DNASU Plasmid Repos-
itory) using the ViraPower HiPerform Lentiviral TOPO Expression Kit (Thermo
Fisher Scientific)[178]. TIMMDC1 cDNA was cloned into the pLenti6.3/V5-TOPO
expression vector and cotransfected into 293FT cells with the packaging plasmid
mix using Lipofectamine 2000. After 24 h, the transfection mix was replaced
with high glucose DMEM supplemented with 10% FBS. After further 72 h, the
viral particle containing supernatant was collected and used for transduction of
the fibroblast cell lines. Selection of stably expressing cells was performed using 5
µg/mL Blasticidin (Thermo Fisher Scientific) for 2 weeks.
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Chapter 5
Discussion
The past decade marks the rise of DNA and RNA sequencing at ever decreasing
costs. Consequently, it has become feasible to investigate multiple genome-wide
layers of information in one project organized by one lab. These advances allowed
me to investigate the consequences of DNA variation on RNA expression using
sequencing data in two projects: i) identify and quantify regulatory mechanisms
that buffer the effect of DNA variation and ii) use RNA-seq information to im-
prove genetic diagnosis of Mendelian disorders beyond genome-information-based
approaches.
5.1 Discussion of negative feedback results
The discussion presented in this section is part of the manuscript ”Negative
feedback buffers effect of regulatory variants” from Bader et al. 2015 [1].
We found that compensatory local trans-regulatory mechanisms buffer typically
15% of RNA level log-ratios caused by naturally occurring cis-regulatory variants
in S. cerevisiae. Local trans mechanisms involve the gene itself (feedback) or trans-
acting variants in its genetic vicinity. Analysis of expression data of heterozygous
deletions indicates that this buffering is primarily due to negative feedback regula-
tion and not due to compensatory mutations. In addition, we did not find evidence
for translational buffering to be common when reanalyzing ribosome profiling data
of a cross between two yeast species, even though translational buffering occurs
for specific instances. The intensity of buffering through local trans regulation
was lower for highly expressed genes, suggesting that the sheer amount of tran-
scripts available for these genes confer robustness against cis-regulatory variants.
In low to middle range of expression, buffering was increasing across the three cat-
egories, non-coding, non-essential coding, and essential coding genes, correlating
with presumed functional importance.
We dissected local regulation into its cis and trans components using a novel
experimental design in which ADE in a yeast hybrid strain was compared against
ADE in a pool of its spores. In contrast, former dissection of local regulation was
performed in two steps [41]. First, polymorphisms in the vicinity of genes that
significantly associated with their expression across a population of spores were
identified (eQTL mapping). Second, the estimated effect of these local eQTLs was
compared to allelic differential expression in a hybrid strain. The advantage of
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our experimental design is first economic, because the spores are pooled whereas
eQTL mapping requires typically dozens of individual spores to be transcription
profiled. Second, our design suffers less from confounders such as batch effects
that can give false associations in eQTL mapping. Third, ADE in the hybrid is
more comparable to ADE in the pool of spores than to eQTL effects because in
the former case the same experimental protocol and the same analysis are applied.
One should note that amplification and sequencing biases could favor one allele
thereby leading to overestimated ADE. However, the same bias applies similarly
to the pool and to the hybrid and thus does not affect our observation that ADE
is lower in the pool than in the hybrid. Our experimental design could be applied
to study other levels of gene regulation where local trans mechanisms, and in
particular regulatory feedback, could play a significant role, including synthesis
and decay of RNA, translation, and protein levels [179].
Our findings have implications for the understanding of dosage compensation, i.e.
the buffering of expression level in case of gene copy number variation. Unlike for
sex chromosomes, the prevalence and the mechanisms for dosage compensation on
autosomes are poorly understood. Buffering in the 10% to 20% range was reported
for a set of seven autosomal single copy deletions in fruit fly [125]. In contrast,
Springer et al. [127] reported a general lack of dosage compensation in yeast. Our
study shows that these observations are more in agreement to each other than they
seem to be. We found that buffering against cis-acting regulatory variants in yeast
is typically of 15% genome-wide, and that Springer and colleagues’ heterozygous
deletion screen was biased for genes with little buffering (about 5%). Hence,
the extent of buffering appears to be conserved from yeast to fly. Moreover, we
found that buffering is primarily due to negative feedback which confers robustness
against single nucleotide polymorphisms and short indels as well, as supported by
the fact that we assessed genes with more than 95% identity between the two
parental strains. Together, these results suggest that dosage compensation of
autosomal genes in higher eukaryotes might be explained to a large extent by
negative feedback, i.e. by a mechanism that generally buffers regulatory variants
rather than by a copy number surveillance pathway.
In 1942, Waddington hypothesized the existence of buffering mechanisms against
genetic variants that would explain the remarkable stability of developmental pro-
cesses among individuals [180, 181]. It is still unclear to date, which buffering
mechanisms act across the stages of phenotypic expression, from DNA to RNA,
protein and cellular phenotypes, and what their respective contribution is. Robust-
ness against coding variations can be explained by redundancy, such as diploidy,
copy number variation, and functional duplication [182, 183]. Our data show that
already at the level of RNA expression, buffering is widespread. We could estimate
its effect and identified negative feedback as the predominant mechanism. Protein
abundance of orthologous genes has been shown to be more conserved than mRNA
abundance across all domains of life ranging from bacteria to fungi and primates
[184–186]. Thus, further mechanisms buffering regulatory variants downstream of
RNA expression remain to be identified [187, 188]. One possibility is that negative
feedback is also common for controlling protein levels.
Buffering plays an important role in evolution because it confers robustness to mu-
tations on the one hand and allows the accumulation of cryptic genetic variants
in the population that might give selective advantage under new environmental
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conditions on the other hand. In this context, a capacitor is a switch capable of
releasing previously cryptic heritable variation [189]. Since feedback loops them-
selves can be impaired, through mutations as in the case of ROX1 or environmental
changes, we suggest that negative feedback loops could function as capacitors.
5.1.1 Conclusion
In the negative feedback project discussed above, gene expression from a hybrid
of two yeast strains and its spores was measured. We developed a new statistical
model that allowed us to quantify local trans regulatory effects with our new
experimental design using an established statistical software package. Local trans
regulation was found to buffer the effect of cis-regulatory elements, in contrast to
translational efficiency. Furthermore, this buffering is stronger for lower expressed
genes and genes that are essential. We could also clarify that local trans buffering
acts primarily through negative feedback loops. In general, negative feedback
loops are likely to confer robustness at multiple stages of gene regulation not only
in yeast, but also in higher organisms.
5.1.2 Outlook
Our advanced statistical model can be applied to all existing hybrid gene expression
and ribosome profiling studies (section 1.2.2). With such a reanalysis cis and trans
regulatory mechanisms can be finally compared across multiple species in terms of
affected genes, direction of effect, and effect size. Two recent studies of RNA-seq
in intraspecies hybrids of higher organisms do neither resolve existing conflicts
(section 1.2.3) nor establish analysis standards: A study in drosophila hybrids
reported cis-trans compensation using RNA-seq data [190]; In the other study
RNA-seq and ribosome profiling data were used to show translational buffering in
mice hybrids [191]. Further mechanistic insights can also be expected from allele-
specific protein expression data from hybrid organisms [179]. To combine all these
ideas, RNA-seq, ribosome profiling, and allele-specific protein expression could be
investigated in mouse hybrids viable with one allele of one chromosome deleted.
Depending on the haploid region’s size in the mice hybrids, local trans effects
can be measured genome-wide in mammals for RNA, translation, and protein
regulatory mechanisms.
5.2 Discussion of genetic diagnosis results
The discussion presented in this section is part of or adapted from the manuscript
”Genetic diagnosis of Mendelian disorders via RNA sequencing” from Kremer,
Bader et al. 2016 [3].
Altogether, our study demonstrates the utility of RNA sequencing in combination
with bioinformatics filtering criteria for genetic diagnosis by i) discovering a new
disease-associated gene, ii) providing a diagnosis for 10% (5 of 48) of undiagnosed
cases, and iii) identifying a limited number of strong candidates. We established a
pipeline for the detection of aberrant expression, aberrant splicing and mono-allelic
expression of rare variants, that is able to detect significant outliers, i.e. a median
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of 1, 5, and 6, respectively. Overall, for 36 patients our pipeline provides a strong
candidate gene, i.e. a known disease-causing or mitochondrial protein-encoding
gene, like MGST1 (Fig 5.1A, Supplementary Table 1). This manageable amount,
similar to the median number of 16 genes with rare potentially bi-allelic variants
detected by WES, allows manual inspection and validation by disease experts.
While filtering by frequency is highly efficient when focusing on the coding region,
frequency filtering is not as effective for intronic or intergenic variants identified by
whole genome sequencing. The loss-of-function character observed on RNA level
thus improved interpretation of VUS identified by genotyping.
We focused our analysis on one sample preparation pipeline, which has several
advantages. Based on our experience, expression outliers can only reliably be de-
tected after extensive normalization process. This needs information about all
technical details starting from the biopsy, growth of the cells, to the RNA ex-
traction and library preparation. Usually not all this information is available in
published data sets. For detecting aberrant splicing such as new exons, we would
recommend not to mix different tissues because splicing can be tissue-specific.
Mono-allelic expression is the most robust of all criteria in this respect because it
only relies on read counts within a sample. Overall, we recommend not relying
on a single sample being compared to public RNA-seq datasets. Instead, RNA-
seq should be included in the pipeline of diagnostic centers in order to generate
matching controls over time. The situation is similar for whole exome and whole
genome sequencing, where the control for platform-specific biases is important.
Here, we included genetically diagnosed patients in our RNA-seq analysis pipeline
to increase the power for the detection of aberrant expression and aberrant splicing
in fibroblast cell lines. However, when applied to the 40 diagnosed cases with
WES and RNA-seq available, aberrant splicing detected 6 out of 8 cases with a
causal splicing variant, mono-allelic expression recovered 3 out of 6 patients with
heterozygous missense variants compound with a stop or frameshift variant, and
aberrant expression recovered 3 out of 9 stop variants. Counterintuitively, only
one of the 9 frame-shift variants did lead to a detectable RNA defect, i.e. mono-
allelic expression of a near splice site intronic variant within a retained intron. The
partial recovery of stop and frameshift variants may reflect incomplete non-sense
mediated decay. For none of the 14 genes where missense variants were disease
causing, a RNA defect could be detected with our pipeline. This is expected, since
missense variants more likely affect protein function rather than RNA expression
(Supplementary Table 4).
To our surprise, many newly diagnosed cases were caused by a defective splicing
event, which caused loss of function (Fig 5.1B), confirming the increasing role
of splicing defects in both Mendelian [192, 193] and common disorders [131]. In
the case of TIMMDC1, the causal variant was intronic, and thus not covered by
WES. Even when detected by WGS, such deep intronic variants are difficult to
prioritize from the sequence information alone. Here, we showed that RNA-seq of
large cohorts can provide important information about intronic positions that are
particularly susceptible to affect splicing when mutated. We showed that private
exons often arise from loci with weak splicing of about 1%. This suggests that
rare variants affecting such cryptic splice sites are more likely to affect splicing
and that these can be detected as positions with low yet consistent splicing. We
reason that analysis of a RNA-seq compendium of healthy donors across multiple
5.2. DISCUSSION OF GENETIC DIAGNOSIS RESULTS 71
Aberrant expression
Aberrant splicing
Mono-allelic expression
A
A
A
A
A
G
A
C
an
d
id
at
es
p
er
 s
am
p
le
1± 1
5± 3
6± 3
M
G
S
T
1
C
LP
P
A
LD
H
18
A
1
M
C
O
LN
1
T
IM
M
D
C
1
m/z
Proteomics/Western blot
Complementation
wt
Disease associated
variant detected
Supplementation
D
et
ec
te
d
 b
y
V
al
id
at
ed
 b
y
A
TIMMDC1
*
*
MCOLN1
CLPP
*
- 
- 
- 
- 
- 
- 
- - 
- 
- 
- - 
- 
- 
- 
- 
B
Figure 5.1: Validation summary. (A) Discovery and validation of genes with
RNA defects in newly diagnosed patients, i.e. TIMMDC1 (n=2 patients), CLPP,
ALDH18A1, and MCOLN1, and patients with strong candidates, i.e. MGST1.
The median number (± median absolute deviation) of candidate genes is given per
detection strategies. Dotted check, manual inspection not statistically significant.
(B) Schematic representation of variant causing splicing defects for TIMMDC1
(top, new exon red box), CLPP (middle, exon skipping and truncation), and
MCOLN1 (bottom, intron retention). Variants are depicted by a red star.
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tissues such as GTEx [194] could provide tissue-specific maps of cryptic splice sites
useful for prioritizing intronic variants.
Genetic disorders typically show specificity to some tissues, some of which might
not be easily accessible for RNA-sequencing. It is therefore natural to question
whether transcriptome sequencing of an unaffected tissue can help diagnosis. Here,
we performed RNA-seq on patient derived dermal fibroblast cell lines. The fibrob-
last cell lines are the byproducts of muscle biopsies routinely undertaken in the
clinic to biochemically diagnose mitochondrial disorders with enzymatic assays.
By using fibroblast cell lines we overcome the limited accessibility of the affected
tissues, which in the case of mitochondrial disorders are often high energy demand-
ing tissues like brain, heart, skeletal muscle or liver. It turns out that many genes
with a mitochondrial function are expressed in most tissues [195], including fi-
broblasts. Hence, extreme regulatory defects such as loss of expression or aberrant
splicing of genes encoding mitochondrial proteins can be detected in fibroblasts,
even though the physiological consequence on fibroblasts might be negligible. This
property might be true for other diseases: the tissue-specific physiological conse-
quence of a variant does not necessarily stem from tissue-specific expression of the
gene harboring the variant. In many cases, tissue-specificity might be due to en-
vironmental or cellular context, or from tissue-specific expression of further genes.
Hence, tissue-specificity does not preclude RNA-seq of unaffected tissues from re-
vealing the causative defect for a large number of patients. Moreover, non-affected
tissues have the advantage that the regulatory consequences on other genes are
limited and therefore the causal defects are more likely to stand out as outliers
[196].
Parallel to our effort, another study systematically investigated the usage of RNA-
seq for molecular diagnosis with a similar sample size, using muscle biopsies from
rare neuromuscular disease patients [193]. Analogously to our approach, not only
exome sequencing-based VUS candidates were validated, but also new disease-
causing mechanisms identified using RNA-seq data. Despite a few differences in
the approach (expression outliers were not looked for, only samples of the affected
tissues were considered and using samples of healthy donors as controls), the results
are in line with ours whereby aberrant splicing also turns out to be a frequent
disease-causing event. Moreover, the success rate was even higher (35%) confirming
the relevance of using RNA-seq for diagnosis of Mendelian disorders.
In conclusion, we predict that RNA sequencing will become an essential companion
of genome sequencing to address undiagnosed cases of genetic disease.
5.2.1 Conclusion
In the genetic diagnosis project discussed above, RNA-seq was performed on cell
lines from patients that were likely to have mitochondrial disorder. We imple-
mented three strategies to systematically prioritize genes for RNA defects: i)
aberrant expression, ii) aberrant splicing, and iii) mono-allelic expression. Our
approach complements the common diagnosis pipeline based on DNA variants
and therefore helped to diagnose the disease-causing gene in 7 unrelated families.
The diagnosis pipeline presented here is generally applicable to other Mendelian
diseases and can become routine in addition to WES or whole genome sequencing.
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5.2.2 Outlook
A systematic large-scale application of proteomics for diagnosis of Mendelian dis-
orders has not been conducted, yet. Thus, including proteomics into the diagnosis
process would complete the view on the central dogma’s products. With pro-
teomics not only aberrant protein expression can be detected, but also variants
can be prioritized that have a direct effect on proteins. Yet, protein information
needs to be interpreted with great care, since observed protein defects can indicate
both cause and consequences of a disease. It is necessary to gather more experience
on diagnosis standards with transcriptomics and proteomics analysis for further
diseases. As a vision for future disease diagnosis, clinicians ask for and interpret a
patient’s omics-profile the same way they use blood panels today.
74 CHAPTER 5. DISCUSSION
Chapter 6
Appendix
6.1 Acronyms
ADE allelic differential expression
eQTL expression Quantitative Trait Loci
GWAS genome-wide association study
MAE mono-allelic expression
NHDF normal human dermal fibroblasts
RNA-seq RNA sequencing
ROS reactive oxygen species
SNV single nucleotide variant
VUS variant of unknown significance
WES whole exome sequencing
6.2 Appendix for the chapter on negative feed-
back
This section corresponds to the results presented in chapter 2
The supplementary information presented in this section is part of the manuscript
”Negative feedback buffers effect of regulatory variants” from Bader et al. 2015 [1].
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Figure 6.1: Correlation between cis detection and expression. Analog
to figure 2.9A: proportion of cis genes for gene categories (purple shadings) and
expression level terciles (grouped bars). The applied thresholds for false discovery
rate (FDR) and absolute fold change (|FC|) are indicated for each plot (title).
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Figure 6.2: Detailed figure 2.9C and 2.9D. Buffering coefficient compared
against the ranks of expression level for all gene categories (top). A significant
one-sided Spearman correlation test (caption) confirmed the trend in Fig 2.9C as
well as for Fig 2.9D (one-sided Wilcoxon test, bottom)
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Figure 6.3: Evaluation of different thresholds. The figures 2.9C, 2.9D and
2.10C (left to right) are generated for different sets of cis genes. These cis gene
sets vary in the false discovery rate (fdr) and absolute fold change (fc) filter that
was applied (title) and therefore also in size (n, increasing top to bottom).
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Figure 6.4: Detailed buffering environmental response. Buffering coefficient
compared against the ranks of environmental response [45]. A one-sided Spearman
correlation test (title) confirmed the trend in Fig 2.10C.
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CBA
Figure 6.5: Comparison of DESeq2-based test for ADE and the test de-
scribed by [118]. (A) Empirical cumulative distribution of log2-fold change of
RNA expression level between the two biological replicates in the S. cer x S. par
hybrid (black), 1.96 times the median standard deviation of log2-expression lev-
els across biological replicates in the same hybrid (vertical dashed line), log2-fold
change of allelic expression ratio among genes with a significant allelic differential
expression at a nominal P -value of 0.05 according to the originally used statistical
test based on [118] (blue) and according to the approach developed here based on
DeSeq2 (red). (B) Same as Supplementary Fig 2.4C, but the FDR threshold of
0.05 (red) is used instead of 0.2 to match the cutoff used by [51] based on Bullard
test. (C) Same as (B) using the originally used statistical test based on [118].
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Figure 6.6: Calibration of buffering coefficient and testing. (A) Simu-
lated genome-wide buffering coefficient (x-axis, Methods) versus median observed
raw buffering coefficient (y-axis). Linear regression (red line) is used to calibrate
observed raw buffering coefficients. (B) Analogous to (A), but for [51] data (Meth-
ods). Here too, a linear model gives a good calibration. (C) Distribution of median
buffering coefficient across genes under independence of cis and local trans effects
(1,000 permutations and dataset simulations, methods). The distribution is cen-
tered at zero (dashed line, median=-0.01) confirming with a distinct simulation
scheme the correctness of the calibration. The observed median buffering coeffi-
cient (solid black line) is larger than on any dataset simulated under independence
assumption (Bootstrap P -value = 0.001). (D) Analogous to (C), but for [51]
data (Methods). The distribution is centered at zero (dashed line, median=-0.02)
confirming with a distinct simulation scheme the correctness of the calibration.
However, the observed median buffering coefficient (solid black line) is not signifi-
cantly large (Bootstrap P -value = 0.88).
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6.3 Appendix for the chapter on genetic diagno-
sis
This section corresponds to the results presented in chapter 3.
The supplementary information presented in this section is part of the manuscript
”Genetic diagnosis of Mendelian disorders via RNA sequencing” from Kremer,
Bader et al. 2016 [3].
6.3.1 Appendix figures for the chapter on genetic diagnosis
Figure 6.7: RNA protein rank correlation. Histogram of spearman correlation
of RNA and protein levels for each patient with proteomics data available (n=31).
Median is highlighted (green line).
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Figure 6.8: Percent spliced in distributions. (A) The densities of genome-
wide percent spliced in (Ψ) 5’ and 3’ values grouped by their GENCODE anno-
tation status: Both sides of junction are annotated (green), only one side of the
junction is annotated (orange), and no side of the junction is annotated (blue). (B)
The expectation maximization (EM) fitted splice class model based on the GEN-
CODE annotation status. Each line represents the probability density belonging
to a splice class given a Ψ-value. (C) The convergence of the EM algorithm. Each
point represents the average ln-likelihood of the EM-fit after a specific iteration
cycle (n=250).
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Figure 6.9: Variant filter for exome and genome sequencing. The different
filtering steps are explained in detail in the Methods section. (A) Whole exome
sequencing data filtered for candidate genes per patient that match the filter cri-
teria. (B) Analog to (A), but for whole genome sequencing data. (C) Analog to
(A), but for variants that match the filter criteria. (D) Analog to (B), but for
variants that match the filter criteria. The whole genome sequencing data is based
on the two TIMMDC1 deficient patients #35791 and #66744.
6.3.2 Appendix case reports for the chapter on genetic di-
agnosis
Informed consent was obtained from all affected individuals or their guardians in
case of minor study participants. The study was approved by the ethical committee
of the Technische Universität München.
Patient #35791 TIMMDC1
Variant: TIMMDC1 c.[596+2146A>G]; [596+2146A>G], variants not listed in
any database.
This boy was born at term to non-consanguineous Greek parents after uneventful
twin pregnancy (dizygotic twins) via cesarean delivery (weight 2450 g, length 48
cm, head circumference 33 cm). He did not show obvious dysmorphia. Shortly
after birth, he was noted to have muscular hypotonia and poor feeding behav-
ior. During his first year of life developmental delay and failure to thrive be-
came evident. Diagnostic work-up revealed sensorineural deafness and brain MRI
showed enlarged ventricles and megacisterna magna. MR-spectroscopy as well
as metabolic work-up in body fluids failed to detect specific abnormalities. Bio-
chemical analysis of fibroblast and muscle tissue demonstrated a severe isolated
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complex I deficiency (16% of lowest control). He developed muscle wasting and a
dyskinetic movement disorder, never achieving his developmental milestones and
suffered from recurrent respiratory infections, finally leading to his death at the
age of 30 months.
Patient #66744 TIMMDC1
Variant: TIMMDC1 c.[596+2146A>G]; [596+2146A>G], variants not listed in
any database.
This boy was the only child of consanguineous parents from Northern Africa. Preg-
nancy, delivery and birth parameters were normal. Symptoms were first noted at
the age of 6 months when he presented with muscular hypotonia, delayed acquisi-
tion of motor milestones, and nystagmus with altered electroretinogram and evoked
visual potentials. An acute episode with abnormal eye movements, myoclonus, and
loss of consciousness, followed by cerebellar syndrome, led to the diagnosis of Leigh
syndrome, confirmed on a CT scan showing hypersignal in basal ganglia and mildly
elevated lactate levels in blood. Subsequent NMR brain imaging was however nor-
mal. Biochemical analysis of muscle tissue showed a predominant complex I defect
(15% of lowest control). Large-scale deletions and depletion of muscle mitochon-
drial DNA and common mtDNA mutations, including those involving MT-ATP6,
were excluded. At one year of age, he presented with profound hypotonia, cerebel-
lar syndrome with severe dysmetria, delayed mental development, and peripheral
neuropathy. His lactate levels in blood and urine were repeatedly normal despite
severe clinical condition. He died at 20 months of age.
Patient #96687 TIMMDC1
Variant: TIMMDC1 c.[596+2146A>G]; [596+2146A>G], variants not listed in
any database.
This boy was born after uneventful pregnancy via spontaneous delivery to healthy,
non-consanguineous parents from Germany (weight 4180 g, length 57 cm, head cir-
cumference 36 cm). Starting from the age of 3 months poor feeding behaviour, mus-
cular hypotonia, and failure to thrive were noted. In the following, developmental
delay and muscle wasting became evident. He showed severe cognitive/language
impairment, and never achieved ambulation. Starting from the age of four years,
the patient developed severe therapy-resistant epilepsy. Brain MRI studies as well
as metabolic work-up did not reveal any specific abnormalities. Of note, two older
siblings died due to unexplained neurodegenerative disorders with severe epilepsy.
Patient #73804 MGST1
This boy was born after uneventful pregnancy via spontaneous delivery to healthy,
non-consanguineous German parents (weight 4050 g, length 56 cm, head circum-
ference 37 cm). Soon after birth, his parents noted that he was less active and
unusually quiet and did not fix or follow objects. Eye examinations suggested cor-
tical or central blindness. In addition, hearing testing was repeatedly abnormal.
During the first year of life severe developmental delay became evident and he
developed epilepsy. Brain MRIs demonstrated rapidly progressive brain atrophy.
Biochemical analysis of muscle tissue revealed a combined deficiency of complex III
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(75% of lowest control) and complex V (67% of lowest control). Metabolic work-up
was otherwise normal. He never showed developmental progress and at the current
age of 17 years he has severe intellectual disability and is wheelchair-bound. Of
note, his clinical course as well as biochemical and neuroimaging findings, showed
similarities to a patient suffering from thioredoxin 2 deficiency, a recently described
disorder of mitochondrial oxidative stress regulation [135].
Patient #58955 CLPP
Variants: CLPP, c.[661G>A];[661G>A], allele frequency 1.2× 10−5 in ExAC.
This girl was the third child of healthy consanguineous parents (first cousins) of
Turkish origin. She was born at term by spontaneous delivery after an uneventful
pregnancy (weight 2755 g, length 49 cm, head circumference 37 cm). One brother,
aged 17 years is healthy; one brother, aged 13 years, suffers from sensorineural
deafness diagnosed at age 2 years.
Her parents noted muscular weakness from the first week of life. When she
presented at age 2 months, she was microcephalic (1 cm < 3rd percentile) and
showed generalized muscular hypotonia. Echocardiography demonstrated mild
hypertrophic cardiomyopathy. Metabolic analysis disclosed repeatedly metabolic
acidosis with elevated lactate levels (2.8 to 9.0 mmol/l, normal < 2.3 mmol/l).
Fumaric acid, 2-oxo-glutaric acid, and methylmalonic acid were mildly elevated in
urine. Brain MRI at the age of 3 months showed no significant abnormality. Bio-
chemical analysis of fresh muscle tissue showed decreased complex IV activity (26%
of lowest control) and the coenzyme Q10 content was decreased (30% of lowest con-
trol). Muscle immunohistochemistry revealed near absent of immunoreactivity for
complex IV subunits. Subsequently, progressive developmental delay, persistent
microcephaly, and deafness became evident. A percutaneous gastroenterostomy
(PEG) was inserted for chronic feeding difficulties. She developed epilepsy (West-
syndrome) and was treated with Topiramat, Levetiracetam and Lamotrigen. Left
ventricular hypertrophy initially progressed but stabilized under treatment with
propranolol. She is currently 5 years of age and has microcephaly, deafness, severe
psychomotor retardation, and moderate left ventricular hypertrophy.
Patient #80256 ALDH18A1
Varaints: ALDH18A1, c.[1864C>T];[1988C>A], allele frequency 0.82 × 10−5; not
listed in ExAC.
This boy was the first child of healthy non-consanguineous German parents. Pre-
natal ultrasound revealed intrauterine growth retardation. He was born without
complications after 39 weeks of gestation (weight 2640 g, length 49 cm, head cir-
cumference 33.5 cm). Following birth, bilateral congenital cataract and multiple
small haemangiomas were noted. In the first months of life, he developed muscular
hypotonia, developmental delay, severe failure to thrive, and microcephaly. Brain
MRI revealed hypoplasia of the corpus callosum, lack of insular opercularization,
and reduced myelination. Moreover, the child developed drug-resistant epilepsy. A
metabolic work-up showed no significant abnormalities. Muscle biopsy at age 2.5
years showed no significant morphological abnormality, whilst substrate oxidation
and enzyme activities of mitochondrial complexes I-V were within normal limits.
His onward clinical course was characterized by severe, global developmental delay,
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dyskinetic movement disorder, and epilepsy. He died at the age of 4 years from
pneumonia and respiratory failure.
Patient #62346 MCOLN1
Varaints: MCOLN1, c.[681-19A>C];[832C>T], allele frequency 0.83 × 10−5; not
listed in ExAC.
This boy was the third child of healthy, non-consanguineous French parents. Preg-
nancy and delivery were uneventful, whilst birth parameters and early psychomotor
development of the child were normal. However, speech development was delayed,
the patient acquiring language at the age of 4 years. At the age of 11 years,
he began to experience psychomotor regression and progressive visual loss due to
degenerative retinopathy. He developed cerebellar ataxia, hyperreflexia, external
ophthalmoparesis, bilateral corneal clouding, and abnormal behavior. The associ-
ation of corneal clouding with a degenerative retinopathy and psychomotor regres-
sion was suggestive of mucolipidosis, but none of the enzymatic tests available for
mucolipidosis type 1, 2, and 3 revealed an enzyme deficiency in blood leukocytes.
Muscle biopsy showed moderate subsarcolemmal accumulation of mitochondria.
At the current age of 47 years he has severe walking difficulties due to ataxia
and blindness. On examination, he has cerebellar ataxia, hyperreflexia, external
ophthalmoparesis predominating in vertical gaze, bilateral corneal clouding, and
abnormal behavior (easily frightened, sometimes aggressive). Spontaneous speech
is markedly reduced.
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